var title_f37_14_38112="Beclomethasone: Patient drug information";
var content_f37_14_38112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Beclomethasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/51/16180?source=see_link\">",
"       Beclomethasone (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/17/26901?source=see_link\">",
"       Beclomethasone (oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11158 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38112=[""].join("\n");
var outline_f37_14_38112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/51/16180?source=related_link\">",
"      Beclomethasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38113="Patient information: Pericarditis in adults (The Basics)";
var content_f37_14_38113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16976\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/27/432\">",
"         The pericardium of the heart",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/53/12115\">",
"         Patient information: Pericarditis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pericarditis in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pericarditis-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H6662567\">",
"      <span class=\"h1\">",
"       What is pericarditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pericarditis is a condition that causes irritation of the tissue around your heart. This tissue (called the pericardium) forms a sac that protects your heart and keeps it from rubbing against nearby organs (",
"      <a class=\"graphic graphic_figure graphicRef69323 \" href=\"mobipreview.htm?0/27/432\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662584\">",
"      <span class=\"h1\">",
"       What are the symptoms of pericarditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of pericarditis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Chest pain is the most common pericarditis symptom. It can be a sharp pain or a dull ache. You might feel pain in the front of your chest, your shoulder, or your upper back.",
"     </p>",
"     <p>",
"      If you have sharp chest pain, it might get worse when you take a deep breath. If the pain is a dull ache, it might get better when you sit up and lean forward.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662599\">",
"      <span class=\"h1\">",
"       Is there a test for pericarditis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will ask you about your symptoms and do one or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An electrocardiogram (ECG or EKG)&nbsp;&mdash; This test measures the electrical activity in your heart.",
"       </li>",
"       <li>",
"        An echocardiogram&nbsp;&ndash; This test uses sound waves to create an image of your heart as it beats.",
"       </li>",
"       <li>",
"        Chest X-ray &ndash; An X-ray can show if there is a large amount of fluid around your heart. &nbsp;",
"       </li>",
"       <li>",
"        Blood tests&nbsp;&mdash; These measure the levels of certain proteins in your blood, which hold clues about the health of your heart. Certain proteins go up in response to pericarditis. Doctors can measure the levels of these proteins to check for pericarditis and to see if it is improving.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662614\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. See your doctor or nurse right away if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have chest pain",
"       </li>",
"       <li>",
"        You feel short of breath, weak, or faint",
"       </li>",
"       <li>",
"        You have swelling in your legs or other parts of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you think you might be having a heart attack,",
"      <strong>",
"       call 9-1-1 right away",
"      </strong>",
"      . Do not try to get to the hospital on your own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662629\">",
"      <span class=\"h1\">",
"       How is pericarditis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatments for pericarditis are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to reduce pain and inflammation, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        ,",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Motrin",
"        <sup>",
"         &reg;",
"        </sup>",
"        ), or",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/34/550?source=see_link\">",
"         indomethacin",
"        </a>",
"        (brand name: Indocin",
"        <sup>",
"         &reg;",
"        </sup>",
"        )",
"       </li>",
"       <li>",
"        A medicine called",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/40/40580?source=see_link\">",
"         colchicine",
"        </a>",
"        (brand name: Colcrys",
"        <sup>",
"         &reg;",
"        </sup>",
"        ) &nbsp;",
"       </li>",
"       <li>",
"        Rest",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you need more treatment, your doctor can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give you steroids and other medicines to reduce inflammation (not the same steroids athletes take to build up muscle)",
"       </li>",
"       <li>",
"        Do surgery to remove swollen, irritated tissue from around the heart &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H6662644\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/53/12115?source=see_link\">",
"       Patient information: Pericarditis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/14/38113?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16976 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-DF5911362B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38113=[""].join("\n");
var outline_f37_14_38113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662567\">",
"      What is pericarditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662584\">",
"      What are the symptoms of pericarditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662599\">",
"      Is there a test for pericarditis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662614\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662629\">",
"      How is pericarditis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6662644\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/27/432\">",
"      The pericardium of the heart",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/53/12115?source=related_link\">",
"      Patient information: Pericarditis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38114="Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)";
var content_f37_14_38114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16156\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"         Organs inside the abdomen (belly)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/25/24979\">",
"         Patient information: Cirrhosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/49/16147\">",
"         Patient information: Treatment for type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/44/33475\">",
"         Patient information: Type 2 diabetes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/3/44084\">",
"         Patient information: Cirrhosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/22/9572\">",
"         Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/37/36436\">",
"         Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/4/6212\">",
"         Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/47/12018\">",
"         Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nonalcoholic-steatohepatitis-nash-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H21262048\">",
"      <span class=\"h1\">",
"       What is nonalcoholic steatohepatitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nonalcoholic steatohepatitis (NASH) is a long-term condition that affects the liver. The liver is a big organ in the upper right side of the belly (",
"      <a class=\"graphic graphic_figure graphicRef64960 \" href=\"mobipreview.htm?39/54/40804\">",
"       figure 1",
"      </a>",
"      ). When people have NASH, fat tissue builds up in their liver, and the liver gets inflamed.",
"     </p>",
"     <p>",
"      People who drink too much alcohol can get a condition similar to NASH. But NASH happens in people who do not drink alcohol or drink only a little alcohol.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262055\">",
"      <span class=\"h1\">",
"       What causes NASH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not know what causes NASH. They do know that NASH happens more often in some people, such as those who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are overweight",
"       </li>",
"       <li>",
"        Have a condition called diabetes mellitus, which causes blood sugar levels to get too high",
"       </li>",
"       <li>",
"        Have high cholesterol",
"       </li>",
"       <li>",
"        Take certain medicines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262062\">",
"      <span class=\"h1\">",
"       What are the symptoms of NASH?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with NASH have no symptoms.",
"     </p>",
"     <p>",
"      Your doctor or nurse might suspect that you have NASH from the results of your routine blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262069\">",
"      <span class=\"h1\">",
"       Will I need more tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects that you have NASH, you will likely have:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        More blood tests",
"       </li>",
"       <li>",
"        An imaging test of the liver, such as an ultrasound, CT, or MRI scan &mdash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A liver biopsy &mdash; During this test, a doctor removes a small sample of tissue from the liver. Then another doctor looks at the sample under a microscope to see if NASH is present. A liver biopsy is the only test that can tell for sure if you have NASH.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262076\">",
"      <span class=\"h1\">",
"       How is NASH treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no cure for NASH. If you take a medicine that could be causing NASH, your doctor will stop or change that medicine.",
"     </p>",
"     <p>",
"      In addition, your doctor will treat your other medical conditions. For example, he or she can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Help you create a weight loss plan, if you are overweight &mdash; If your doctor recommends that you lose weight, it&rsquo;s important to do this slowly. Do not lose more than 3.5 pounds (1.6 kilograms) a week.",
"       </li>",
"       <li>",
"        Treat your high blood sugar, if you have high blood sugar",
"       </li>",
"       <li>",
"        Treat your high cholesterol, if you have high cholesterol",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262083\">",
"      <span class=\"h1\">",
"       Does NASH get worse over time?",
"      </span>",
"      &nbsp;&mdash;&nbsp;NASH does not usually get worse over time. But sometimes, it leads to serious scarring of the liver, called &ldquo;cirrhosis.&rdquo; Cirrhosis can cause different symptoms, such as swelling in the legs, trouble breathing, or feeling tired. If you get cirrhosis, your doctor will talk with you about different possible treatments.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262090\">",
"      <span class=\"h1\">",
"       Do I need to follow up with my doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People who have NASH need to see their doctor for regular check-ups. Your doctor will do follow-up tests on a regular basis. These usually include blood tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H21262097\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=see_link\">",
"       Patient information: Type 2 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=see_link\">",
"       Patient information: Treatment for type 2 diabetes (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=see_link\">",
"       Patient information: Cirrhosis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=see_link\">",
"       Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=see_link\">",
"       Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=see_link\">",
"       Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"       Patient information: Cirrhosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/14/38114?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16156 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F0872C54B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38114=[""].join("\n");
var outline_f37_14_38114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262048\">",
"      What is nonalcoholic steatohepatitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262055\">",
"      What causes NASH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262062\">",
"      What are the symptoms of NASH?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262069\">",
"      Will I need more tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262076\">",
"      How is NASH treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262083\">",
"      Does NASH get worse over time?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262090\">",
"      Do I need to follow up with my doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21262097\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/54/40804\">",
"      Organs inside the abdomen (belly)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=related_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/25/24979?source=related_link\">",
"      Patient information: Cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/37/36436?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=related_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38115="Juvenile spring eruption 1";
var content_f37_14_38115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile spring eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pruritic, erythematous vesicles and crusted papules occurred on the ears of this 7-year-old boy after sun-exposure in the early spring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38115=[""].join("\n");
var outline_f37_14_38115=null;
var title_f37_14_38116="Sulfur and sulfacetamide: Patient drug information";
var content_f37_14_38116=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sulfur and sulfacetamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/56/11141?source=see_link\">",
"     see \"Sulfur and sulfacetamide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AVAR&trade;;",
"     </li>",
"     <li>",
"      AVAR&trade; LS;",
"     </li>",
"     <li>",
"      AVAR&trade;-e;",
"     </li>",
"     <li>",
"      AVAR&trade;-e Green;",
"     </li>",
"     <li>",
"      AVAR&trade;-e LS;",
"     </li>",
"     <li>",
"      BP 10-1;",
"     </li>",
"     <li>",
"      BP Cleansing Wash;",
"     </li>",
"     <li>",
"      Clarifoam&trade; EF;",
"     </li>",
"     <li>",
"      Claris&trade;;",
"     </li>",
"     <li>",
"      Clenia&reg;;",
"     </li>",
"     <li>",
"      Prascion&reg;;",
"     </li>",
"     <li>",
"      Prascion&reg; FC;",
"     </li>",
"     <li>",
"      Prascion&reg; RA;",
"     </li>",
"     <li>",
"      Rosanil&reg;;",
"     </li>",
"     <li>",
"      SSS 10-4;",
"     </li>",
"     <li>",
"      SulfaCleanse&trade; 8/4;",
"     </li>",
"     <li>",
"      Sumadan&trade;;",
"     </li>",
"     <li>",
"      Sumaxin&reg;;",
"     </li>",
"     <li>",
"      Sumaxin&reg; TS;",
"     </li>",
"     <li>",
"      Zencia&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sulfacet-R&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rosacea.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to control seborrheic dermatitis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sulfur, sulfacetamide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use of other skin products may cause more irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If peeling happens, lower the number of times the drug is used.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705352",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cleanser, Wash:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use on clean affected skin 1 or 2 times each day or as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cloth:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wet with water before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well and rinse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Cream, gel, or topical suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected part and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695525",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Plexion SCT&reg; : Allow skin to dry, rinse well, and pat dry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11875 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.102.30.19-3E8788D7EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38116=[""].join("\n");
var outline_f37_14_38116=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013251\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013250\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013255\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013256\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013258\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013253\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013254\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013259\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013260\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?10/56/11141?source=related_link\">",
"      Sulfur and sulfacetamide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38117="Yellow fever vaccine: Pediatric drug information";
var content_f37_14_38117=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Yellow fever vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"    see \"Yellow fever vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/40/9857?source=see_link\">",
"    see \"Yellow fever vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F235040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      YF-VAX&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1042673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1042696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"      see \"Yellow fever vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;6 months and Adults: SubQ: One dose (0.5 mL) &ge;10 days before travel; Booster: Repeat same dosage every 10 years if at continued risk of exposure (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [17D-204 strain]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     YF-VAX&reg;: &ge;4.74 Log",
"     <sub>",
"      10",
"     </sub>",
"     plaque-forming units (PFU) per 0.5 mL dose [single-dose or 5-dose vial; produced in chicken embryos; contains gelatin; packaged with diluent; vial stopper contains latex]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1042700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Use entire contents of provided diluent to reconstitute vaccine. Gently swirl until a uniform suspension forms; swirl well before withdrawing dose. Avoid vigorous shaking to prevent foaming of suspension. Use within 60 minutes following reconstitution; keep suspension refrigerated until used.  Administer by SubQ injection into the anterolateral aspect of the thigh or arm;",
"     <b>",
"      not for I.V. administration.",
"     </b>",
"     If inadvertently administered I.M., the dose does not need to be repeated. Use of expired vaccine is not considered a valid dose and should be repeated after 28 days. For booster doses, if the date of previous vaccination cannot be determined and the patient requires vaccination, the booster dose can be given. Adolescents and adults should be vaccinated while seated or lying down",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1042690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Must be used within 60 minutes of reconstitution; keep reconstituted suspension refrigerated until used.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1042674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To provide active immunity to yellow fever virus to individuals who are either traveling to or living in endemic yellow fever areas (FDA approved in ages &ge;9 months and adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The  Advisory Committee on Immunization Practices (ACIP) recommends vaccination for: Persons traveling to or living in areas at risk for yellow fever transmission; persons traveling to countries which require vaccination for international travel; laboratory personnel who may be exposed to the yellow fever virus or concentrated preparations of the vaccine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Although the vaccine is approved for use in children &ge;9 months of age, the CDC recommends use in children as young as 6 months under unusual circumstances (eg, travel to an area where exposure is unavoidable). Children &lt;6 months of age should",
"     <b>",
"      never",
"     </b>",
"     receive the vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adverse reactions may be increased in patients &lt;9 months or &ge;60 years of age):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, focal neurological defects, headache, malaise, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions (edema, erythema, hypersensitivity, mass, pain, pruritus, rash, warmth)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Guillain-Barr&eacute; syndrome (GBS), hypersensitivity (immediate), vaccine-associated neurotropic disease (rare), viscerotropic disease (rare; may be associated with multiorgan failure)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaccine-associated neurologic disease (YEL-AND) may manifest as meningoencephalitis (neurotropic disease), GBS, acute disseminated encephalomyelitis, and bulbar palsy. Vaccine-associated viscerotropic disease (YEL-AVD) mimics naturally-acquired yellow fever disease; risk may be increased in older patients and those with a history of thymus disease or thymectomy.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1042680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to the vaccine, egg or chick embryo protein, or any component; children &lt;6 months of age (per CDC guidelines) (&lt;9 months of age per manufacturer); acute or febrile disease; breast-feeding; immunosuppressed individuals including those with blood dyscrasias, leukemia, lymphomas, thymic disease, or other malignant neoplasms affecting the bone marrow or lymphatic systems; concurrent immunosuppressive therapy (corticosteroids, alkylating drugs, antimetabolites) or radiation; transplant; family history of congenital or hereditary immunodeficiency; primary and acquired immunodeficiency states including patients with symptomatic HIV infection or CD4+ counts &lt;200/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or &lt;15% of total lymphocytes in ages &le;6 years) (per CDC)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3872061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Malnourished persons may have a decreased response to vaccination. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009 ). Transfusion-related transmission of yellow fever vaccine virus has been reported; wait 2 weeks after immunization with yellow fever vaccine to donate blood. Latex is used in stopper of the vial which may cause allergic reactions in susceptible individuals. May cause fever; reported incidence variable depending on the study, as low as &lt;5% and as high as 10% to 30% has been reported.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1042681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for use in patients who are immunosuppressed due to an increased risk of encephalitis with yellow fever vaccine administration; consider delaying travel or obtaining a waiver letter. Patients on low-dose or short-term corticosteroids are not considered immunosuppressed and may receive the vaccine. Use caution when administering the vaccine to patients with asymptomatic HIV infection with CD4+ counts 200-499/mm",
"     <sup>",
"      3",
"     </sup>",
"     (or 15 to 24% of total lymphocytes in children &lt;6 years of age). Chicken embryos are used in the manufacture of this vaccine; use caution in patients with immediate-type hypersensitivity reactions to eggs; immediate treatment for anaphylactic reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid use in infants &lt;9 months and pregnant women unless travel to high-risk areas are unavoidable; use in infants &lt;6 months of age is contraindicated due to risk of encephalitis. The decision to use in children between 6-9 months of age must weigh the risks of exposure to the virus with the theoretic risks of vaccine-associated encephalitis (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009). Advice regarding use of this vaccine can be obtained from the Division of Vector-Borne Infectious Diseases of the CDC. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. In general, household and close contacts of persons with altered immune competence may receive all age-appropriate vaccines.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxychloroquine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone; Budesonide (Systemic, Oral Inhalation); Corticotropin; Cortisone; Cytarabine (Liposomal); Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Hydroxychloroquine; Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Adverse events were not observed in the mother or fetus following vaccination during the third trimester of pregnancy in Nigerian women; however, maternal seroconversion was reduced. Inadvertent exposure early in the first trimester of pregnancy in Brazilian women did not show decreased maternal seroconversion; no major congenital abnormalities were noted. Cord blood from an infant whose mother was vaccinated during the first trimester tested positive for IgM antibodies; no adverse events were noted in the infant. Vaccine should be administered if travel to an endemic area is unavoidable and the infant should be monitored after birth. Tests to verify maternal immune response may be considered. If a pregnant woman is to be vaccinated only to satisfy an international requirement (as opposed to decreasing risk of infection), efforts should be made to obtain a waiver letter. Women should wait 4 weeks after receiving vaccine before conceiving.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1042702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3883661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A live, attenuated virus vaccine; offers active immunity to disease caused by yellow fever virus",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F3883762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Onset of action: Seroconversion: 10-14 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1042703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/40/9857?source=see_link\">",
"      see \"Yellow fever vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immunity develops by the tenth day and",
"     <b>",
"      WHO",
"     </b>",
"     requires revaccination every 10 years to maintain travelers' vaccination certificates.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1042705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A desensitization procedure is available for persons with severe egg sensitivity. Consult manufacturer's labeling for details. Some countries require a valid International Certification of Vaccination or Prophylaxis (ICVP) showing receipt of vaccine. Certificate is valid beginning 10 days after and for 10 years following vaccination (booster doses received within 10 years are valid from the date of vaccination). The WHO requires revaccination every 10 years to maintain traveler's vaccination certificate. Current requirements and recommendations for immunization related to travel destination can be obtained from the CDC Travelers' Health Web site (www.cdc.gov/travel). All travelers to endemic areas should be advised of the risks of yellow fever disease and all available methods to prevent it. All travelers should take protective measures to avoid mosquito bites.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The following CDC agencies may be contacted if serologic testing is needed or for advice when administering yellow fever vaccine to pregnant women, children &lt; 9 months, or patients with altered immune status:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Division of Vector-Borne Infectious Diseases: 970-221-6400",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Division of Global Migration and Quarantine: 404-498-1600",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2004, 49(RR-10):89-90.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Transfusion-Related Transmission of Yellow Fever Vaccine Virus &minus; California, 2009,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(2):34-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/20094025/pubmed\" id=\"20094025\" target=\"_blank\">",
"        20094025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"International Travel,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 98-104. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/1.7.13",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staples JE, Gershman M, Fischer M, et al, \"Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-7):1-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/14/38117/abstract-text/20671663/pubmed\" id=\"20671663\" target=\"_blank\">",
"        20671663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13021 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-7A5059B635-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38117=[""].join("\n");
var outline_f37_14_38117=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235039\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235040\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042673\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042696\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235021\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235009\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042700\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042690\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042674\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235055\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042680\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3872061\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042681\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300231\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235015\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235017\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235030\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042702\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3883661\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3883762\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042703\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042705\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13021|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=related_link\">",
"      Yellow fever vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/40/9857?source=related_link\">",
"      Yellow fever vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38118="Polyadenylation polymorphism in FSHD";
var content_f37_14_38118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Polyadenylation polymorphism in FSHD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An intact D4Z4 region in chromosome 4 leaves a condensed chromatin state that prevents transcription of the distal",
"    <em>",
"     DUX4",
"    </em>",
"    gene. Chromosome 10q (and non-FSHD chromosome 4 alleles) does not have functional",
"    <em>",
"     DUX4",
"    </em>",
"    transcription elements. In FSHD, D4Z4 contractions in chromosome 4 (4q) lead to an open chromatin that exposes the distal",
"    <em>",
"     DUX4",
"    </em>",
"    gene and a sequence (pLAM) that encodes a poly(A) signal. This results in the transcription of",
"    <em>",
"     DUX4",
"    </em>",
"    , which may be linked to muscle degeneration in FSHD.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Mahadevan MS. Genetics. Exposing a DUX tale. Science 2010; 329:1607. Reprinted with permission from: AAAS. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38118=[""].join("\n");
var outline_f37_14_38118=null;
var title_f37_14_38119="Hantavirus cardiopulmonary syndrome";
var content_f37_14_38119=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hantavirus cardiopulmonary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Brian Hjelle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38119/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/14/38119/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the more than 20 known species of rodent-borne viruses within the genus Hantavirus, family Bunyaviridae, at least 11 are associated with human disease. Two major forms of hantavirus disease are recognized: hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS, also called HPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the agents of HCPS, the most severe forms are associated with Sin Nombre virus (SNV) and the southern (prototypical) form of Andes virus; slightly milder forms are caused by the northern form of Andes virus (Andes-Nort), Laguna Negra virus (LNV), and Choclo virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, case-fatality ratios of HCPS range from 30 to 50 percent for severe forms and 10 to 30 percent for milder forms. The illness caused by Choclo virus (Panama) is the mildest form of HPS, in that it nearly always or always lacks a significant component of cardiac insufficiency and has a markedly lower case-fatality ratio.",
"   </p>",
"   <p>",
"    The clinical manifestations of HCPS will be discussed here. The clinical manifestations of HFRS are discussed elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25544?source=see_link\">",
"     \"Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)\"",
"    </a>",
"    ). The etiologic agents of other human hantavirus diseases and the diagnosis of these pathogens are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4920?source=see_link\">",
"     \"Pathogenesis of hantavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 1993, clinicians working with the Indian Health Service in the Four Corners region of the southwestern United States noted a cluster of cases of a severe respiratory illness affecting previously healthy young adults. The syndrome was characterized by a nonspecific prodrome, followed by the rapid development of noncardiogenic pulmonary edema and hemodynamic compromise, and carried a high mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A rapid response to the newly described syndrome was initiated by the Indian Health Service, the University of New Mexico School of Medicine, state health officials, and the United States Centers for Disease Control and Prevention (CDC). Within weeks, sera from patients was demonstrated to be broadly reactive to conserved regions of viruses of the genus Hantavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Members of this genus previously had been identified as the etiologic agents of hemorrhagic fever with renal syndrome (HFRS), which occurs principally in Europe and Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An extensive rodent trapping campaign was initiated, based upon an early case-control study that identified contact with rodents as the principal risk factor for illness in the Four Corners outbreak and the knowledge that a rodent reservoir was responsible for the transmission of HFRS. Researchers identified an unusually large population of deer mice (Peromyscus maniculatus) with evidence of hantavirus infection by serology and reverse transcriptase PCR (RT-PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. The genetic characterization of a new member of the genus Hantavirus, termed Sin Nombre virus (SNV), followed these developments, and the illness it caused was named hantavirus cardiopulmonary syndrome (HCPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/8-13\">",
"     8-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It soon became clear that HCPS predated the Four Corners outbreak, with retrospective diagnoses being made for cases that occurred as far back as 1959 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/11,12,14\">",
"     11,12,14",
"    </a>",
"    ]. It also became apparent that HCPS due to SNV or closely related viruses occurred throughout North and South America. Between 1993, when HCPS was identified in the United States, and December 2010, 560 confirmed cases were reported from 32 states, the majority of which were in the southwestern United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Cases have also been identified in Canada and Central and South America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/14,17-19\">",
"     14,17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL CASE DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC) defines a clinical case of HCPS as follows: a febrile illness (eg, temperature greater than 101&ordm;F [38.3&ordm;C]) characterized by bilateral diffuse interstitial edema that may radiographically resemble adult respiratory distress syndrome (ARDS), with respiratory compromise requiring supplemental oxygen developing within 72 hours of hospitalization, and occurring in a previously healthy person. Alternatively, a case can be defined as an unexplained respiratory illness resulting in death, with an autopsy examination demonstrating noncardiogenic pulmonary edema without an identifiable cause. These case definitions are not diagnostic of HCPS, but were chosen to be inclusive.",
"   </p>",
"   <p>",
"    The US Public Health Service's national database requires virus-specific laboratory confirmation before a case is recorded as HCPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical progression of hantaviral illnesses advances through several sequential stages discussed below. In some cases, patients will experience a course of illness that is truncated at the earliest stage of illness, the prodromal stage; in many regions outside of North America, patients develop antibodies to hantaviruses with few or no clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically a period of two to three weeks elapses between exposure to a hantavirus and the first symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/20\">",
"     20",
"    </a>",
"    ]. Isolated cases with shorter or longer incubation periods have also been reported. In a study of 11 patients with hantavirus who had well-defined and isolated exposure to rodents, the median incubation period was 14 to 17 days (range 9 to 33 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/20\">",
"     20",
"    </a>",
"    ]. However, in a case that was reported subsequently, the estimated incubation period was approximately seven weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/21\">",
"     21",
"    </a>",
"    ]. Epidemiologic studies have demonstrated that many hantaviruses are inhaled and reach the lung parenchyma where they are taken up by local phagocytes, which are then transported to draining lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prodrome/febrile phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest clinical manifestations of HCPS consist of fever, chills and myalgias, which can be severe in many cases. At this stage, HCPS is difficult to distinguish from other viral syndromes. However, an experienced clinician often suspects HCPS during the prodromal phase of illness because the constellation of clinical findings and setting (eg, likely rodent exposures) are characteristic of HCPS but not of other illnesses.",
"   </p>",
"   <p>",
"    During this two- to eight-day phase, the disease increases in severity at a rapid pace, often leading to nausea, vomiting, weakness, and sometimes diarrhea. Headaches are sometimes prominent. Abdominal pain can be significant enough to mislead the clinician into considering a diagnosis of acute abdomen.",
"   </p>",
"   <p>",
"    Classic features of upper respiratory tract diseases (URI) such as rhinorrhea, pharyngitis, coryza, and ear pain are notably absent in most patients with hantavirus diseases, except for cough. Pharyngitis is sometimes observed in children with HCPS.",
"   </p>",
"   <p>",
"    Some forms of HCPS (eg, Andes-HCPS) can present with conjunctivitis, facial flushing and varying numbers of fine petechiae on the trunk, axillary folds, soft palate, or neck.",
"   </p>",
"   <p>",
"    The prodromal phase is followed by the rapid onset of hypotension and non-cardiogenic pulmonary edema, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiopulmonary phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"cardiorespiratory\" or \"cardiopulmonary\" phase denotes the point at which capillary leak into the pulmonary bed occurs. This phase can last from two to more than seven days depending upon the overall severity of the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/2,22\">",
"     2,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A dry cough often heralds the abrupt transition to the cardiopulmonary phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/23\">",
"     23",
"    </a>",
"    ]. The rapidity with which the features of the prodromal phase progress to shock, coagulopathy (with hemorrhage common in infections due to Andes virus), pulmonary edema, bronchorrhea, arrhythmias, and death have led experienced clinicians to triage patients with hantavirus infection to a tertiary care center at the earliest possible stage of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Once the first signs of cardiopulmonary involvement are apparent, it is not uncommon for the local clinician to be caught in the difficult bind of attempting to transport a critically ill patient to a tertiary care center hours away.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oliguric and diuretic phases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separate phases characterized by oliguria (three to seven days), then diuresis of variable length have been reported for HFRS, but are emphasized less in clinical descriptions of HCPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/10,22,26-28\">",
"     10,22,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Convalescent phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The resolution of the cardiorespiratory phase of HCPS can occur almost as quickly and dramatically as the onset, over periods as short as 24 to 48 hours. However, complete recovery from severe HCPS can be a slow process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest and among the more specific laboratory abnormalities is a rapid decline in the platelet count; this occurs as early as the prodromal phase of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/29\">",
"     29",
"    </a>",
"    ]. Other important but less specific abnormalities include an increase in serum levels of LDH, which often occurs early, and elevations in hepatocellular enzymes and lactate, which occur later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/10,30\">",
"     10,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunoblasts, resembling those that are observed in the lungs and lymphoid tissues of patients with HCPS, become abundant in the blood when the patient advances from the prodromal into the cardiorespiratory stage of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/29\">",
"     29",
"    </a>",
"    ]. This change is concomitant with the appearance of markedly left shifted cells of the granulocytic series. While the decrease in the platelet count appears early in the course of illness, thrombocytopenia does not reliably distinguish those who will develop the most severe forms of the disease from those who will go on to experience a less severe course of illness. By contrast, leukocytosis (as high as 90,000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    and the appearance of immunoblasts are more pronounced in those patients with severe forms of illness.",
"   </p>",
"   <p>",
"    The simultaneous appearance of thrombocytopenia, a left-shifted granulocytic series, and an immunoblast count that exceeds 10 percent of the total lymphoid series is referred to as the diagnostic triad. This triad is sufficiently diagnostic that it is used at centers with substantial experience with HCPS to triage patients for extracorporeal membrane oxygenation (ECMO) and other specialized tertiary care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A decrease in the serum concentration of albumin occurs concomitantly with increases in blood hemoglobin and hematocrit. These abnormalities are regarded as markers for the severity of capillary leak. Increases in partial thromboplastin time and prothrombin time are frequently observed in the more severe forms of hantavirus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT HANTAVIRUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCPS should be suspected in settings in which a patient from a rural area or with potential exposure to wild rodents presents with fever, chills, and myalgias, especially in the presence of nausea and vomiting. Specific serologic diagnosis should be considered in patients with thrombocytopenia, leukocytosis, bilateral interstitial infiltrates, or elevated LDH.",
"   </p>",
"   <p>",
"    It is most useful to obtain a CBC when hantavirus disease is suspected, because thrombocytopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis or leukopenia can be detected at the time of the first or second blood examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/2,10,29,31,32\">",
"     2,10,29,31,32",
"    </a>",
"    ]. Above all, there should be a low threshold for ordering a specific serologic test, since modern antibody tests are accurate and because at least some clinical laboratories are able to complete the testing on the same day that they receive the sample [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are the main method for diagnosis of either acute or remote infection by hantaviruses. By the time symptoms are evident, patients uniformly have antiviral antibodies of the IgM class and most have antibodies of the IgG class. Diagnostic assays include: enzyme linked immunosorbent assays (ELISA), strip immunoblot tests (SIA), Western blot, indirect immunofluorescence (IFA), complement fixation, hemagglutinin inhibition, as well as focus or plaque reduction neutralization tests to detect antibodies to hantaviruses. No diagnostic test for hantavirus has been approved by the US Food and Drug Administration.",
"   </p>",
"   <p>",
"    Acute infection can be distinguished from remote (past) infection by the presence of specific anti-hantavirus IgM (usually the nucleocapsid or N antigen is used) or a fourfold rise in titers of anti-hantavirus IgG.",
"   </p>",
"   <p>",
"    In the United States, those state health departments that offer hantavirus diagnostic testing use IgG and mu-capture IgM ELISAs developed and distributed by the CDC. These ELISAs use recombinantly-expressed N antigen. A similar test is also used in Canada. A Western blot assay using recombinant antigens and isotype-specific conjugates for IgM-IgG differentiation has also been developed, which performs similarly. The Western blot has been largely supplanted by the SIA.",
"   </p>",
"   <p>",
"    Detection of viral RNA by nested reverse transcription-polymerase chain reaction (RT-PCR) in plasma, blood cells, or tissues is also considered diagnostic for hantavirus infection; however these techniques are usually not necessary due to the high diagnostic accuracy of serologic assays. Postmortem diagnosis is accomplished using an immunohistochemical test for N antigen from tissues (kidneys, lung) in paraffin blocks or from detection of viral RNA using reverse transcription-PCR.",
"   </p>",
"   <p>",
"    The diagnosis of hantavirus infection is described at greater length elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=see_link\">",
"     \"Epidemiology and diagnosis of hantavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;By the time pulmonary disease develops, the constellation of pulmonary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac insufficiency, bilateral interstitial infiltrates, fever, rural origin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rodent exposure, thrombocytopenia, leukocytosis and lymphocytic atypia, elevated lactate dehydrogenase, and transaminases are virtually pathognomonic.",
"   </p>",
"   <p>",
"    The differential diagnosis that one might entertain depends upon what other respiratory or septic illnesses are incident in the region. Other respiratory infections to consider include Legionella, Chlamydia, Mycoplasma, and Q fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/30\">",
"     30",
"    </a>",
"    ]. Depending upon the geographic setting and exposure history, septicemic plague or tularemia, leptospirosis, dengue fever, or yellow fever might be entertained. Abdominal manifestations may be sufficiently severe and isolated to lead to consideration of appendicitis or cholelithiasis. Noninfectious etiologies include diseases associated with pulmonary hemorrhage, such as granulomatosis with polyangiitis (Wegener&rsquo;s) and Goodpasture's syndrome. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of surviving HCPS increases with early recognition, hospitalization, and adequate pulmonary and hemodynamic support. This includes intensive care unit monitoring, and the initiation of mechanical ventilation as needed to treat respiratory failure.",
"   </p>",
"   <p>",
"    It is unusual for patients to succumb solely from respiratory failure in centers at which sophisticated ventilatory support is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. Given the role of capillary leak in the development of noncardiogenic pulmonary edema and hypotension, early use of vasopressors for management of hypotension and cautious use of intravenous fluids is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal membrane oxygenation (ECMO) has been used successfully in a number of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/17,26,34\">",
"     17,26,34",
"    </a>",
"    ]. The technique has been used only in patients who were regarded as extremely likely to die from HCPS; in this subset, survival has been about 50 percent. At centers with significant expertise in ECMO, severely compromised cardiac output is considered an especially important factor in deciding which patients are most likely to require this specialized therapy. Patients with a cardiac index of &lt;2.5",
"    <span class=\"nowrap\">",
"     L/min/m2",
"    </span>",
"    despite attempts to resuscitate with pressors and inotropic agents are potential candidates for ECMO. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antiviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is a nucleoside analogue that is effective in HFRS due to Hantaan virus, a different strain of hantavirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/35\">",
"     35",
"    </a>",
"    ]. A prospective, randomized, double-blind, placebo-controlled trial of 242 patients with serologically confirmed Hantaan virus in the People's Republic of China found a sevenfold decrease in mortality among ribavirin-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/36\">",
"     36",
"    </a>",
"    ]. The major side effect of ribavirin was anemia, which reversed upon the completion of therapy. Unfortunately, even in the regions of rural China where HTNV-HFRS is most common, few patients receive intravenous ribavirin therapeutically because of the high cost.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    at clinical-relevant doses was found to prevent seroconversion and markedly diminish viral replication in the deer mouse model, suggesting that it may be premature to completely exclude utility of the drug against SNV, such as in post-exposure prophylaxis or very early in the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    has activity against SNV in vitro, two trials examining the role of this nucleoside analogue for the treatment of HCPS were conducted. However, study design and patient enrollment was insufficient to allow its efficacy to be demonstrated or excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results of an open labeled, nonrandomized trial which enrolled 30 patients between June 1993 and August 1994 did not demonstrate a decrease in mortality with the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/38\">",
"       38",
"      </a>",
"      ]. It was concluded that a randomized, placebo-controlled trial during the prodrome phase would be necessary to assess drug efficacy.",
"     </li>",
"     <li>",
"      An NIH-sponsored, double-blind, placebo-controlled trial to further evaluate the role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      therapy in HCPS enrolled 36 patients from 1996 to 2001; among the 23 patients with confirmed SNV infection, 10 received intravenous ribavirin and 13 received placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/39\">",
"       39",
"      </a>",
"      ]. The study was terminated before the target number of subjects was enrolled due to slow accrual. Overall, 8 of 10 ribavirin recipients and 11 of 13 placebo recipients survived at day 28 of the study. In addition, there were no significant differences or trends between groups regarding measures of shock or respiratory failure. The authors concluded, that although the study lacked adequate power to determine whether ribavirin was safe or effective, the lack of trends favoring its use suggested that ribavirin did not have a significant role in the treatment of hantavirus cardiopulmonary syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    off protocol cannot be recommended for established HCPS. Because of the virus's known susceptibility to ribavirin in cultured cells and in the deer mouse model, the drug might still be considered should the syndrome be recognized during an exceptionally early stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the limited treatment options and high case-fatality rate of HCPS, prevention of disease is of obvious importance. Recommendations from the CDC focus on measures to limit contact with potentially infectious rodents in affected areas, particularly in indoor, poorly ventilated spaces.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All holes that might allow rodents to enter buildings should be sealed with steel wool, wire screen, cement or other patching material.",
"     </li>",
"     <li>",
"      Seldom used buildings should be opened and aired out prior to entry.",
"     </li>",
"     <li>",
"      Potential nesting sites near homes should be eliminated by clearing brush and debris from around the foundation and elevating hay, woodpiles, and garbage cans. If nesting sites are discovered, latex gloves should be worn during clean-up, and nests should be soaked with 10 percent bleach or detergent solution prior to removal to prevent aerosolization. Latex gloves should be disinfected prior to removal and hands should be washed thoroughly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If heavy infestation is present in an area where HCPS has been reported, it is recommended that the appropriate local, state, or federal health officials be consulted prior to clean-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vaccine development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to produce vaccines for hantaviruses have favored those products that elicit neutralizing antibodies, a preference that can be traced to early studies that showed a strong correlation between the efficacies of vaccine preparations and the titers of neutralizing antibodies they engendered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Yet, passive antibody therapy has not been actively pursued for hantaviruses, in part because of the widespread recognition that patients exhibit potent antibody responses by the time of presentation. It is interesting to observe that evidence has accrued demonstrating that patients who present with high titers of neutralizing antibodies to SNV are those who are destined to have milder disease, whereas lower titers of neutralizing antibodies tend to occur in patients who died or required ECMO salvage therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, few vaccines are licensed or available worldwide. In China and Korea, killed-virus vaccines are available for HTNV",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    SEOV but their expense precludes their widespread usage in the most heavily-affected regions of China. No vaccines are available for SNV, PUUV, DOBV, LNV or Andes virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38119/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the agents of HCPS, the most severe forms are associated with Sin Nombre virus (SNV) and Andes virus. Case-fatality ratios of HCPS range from 30 to 50 percent for severe forms and 10 to 30 percent for milder forms. Many hantaviruses are shed in the urine, feces, or saliva of acutely-infected reservoir rodents. It is suspected that much, if not all, transmission to man occurs via the aerosol route (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Historical perspective'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typically a period of three weeks elapses between exposure to a hantavirus and the first symptoms. The syndrome is characterized by a nonspecific prodrome, followed by the abrupt development of noncardiogenic pulmonary edema and hemodynamic compromise. The resolution of the cardiorespiratory phase of HCPS can emerge almost as quickly and dramatically as the onset, in as little as 24 to 48 hours (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Laboratory abnormalities include thrombocytopenia, leukocytosis, hemoconcentration, hypoalbuminemia, and an increase in serum LDH. The simultaneous appearance of thrombocytopenia, a left-shifted granulocytic series, and an immunoblast count that exceeds 10 percent of the total lymphoid series is referred to as the diagnostic triad (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Laboratory findings'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      HCPS should be suspected in settings in which a patient from a rural area or with potential exposure to wild rodents presents with fever, chills, and myalgias. Specific serologic diagnosis should be considered in patients with bilateral interstitial infiltrates, thrombocytopenia, leukocytosis with a left-shifted granulocytic series, or elevated LDH. We recommend prompt serologic testing. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'When to suspect hantavirus disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment for HCPS is mainly supportive. This includes intensive care unit monitoring and the initiation of mechanical ventilation as needed to treat respiratory failure secondary to capillary leak (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above). We recommend:",
"     </li>",
"     <li>",
"      Early use of vasopressors for management of hypotension and cautious use of intravenous fluids due to the associated capillary leak syndrome (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      No specific antiviral therapy for hantavirus is available. An NIH sponsored randomized, placebo-controlled trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      was terminated early due to slow accrual. The authors concluded, that although the study lacked adequate power to determine whether ribavirin was safe or effective, the lack of trends favoring its use suggested that ribavirin did not have a significant role in the treatment of hantavirus cardiopulmonary syndrome.",
"     </li>",
"     <li>",
"      Based upon these observations, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      off protocol cannot be recommended for established HCPS (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Extracorporeal membrane oxygenation (ECMO) is utilized in centers with expertise in HCPS based upon uncontrolled but promising clinical experience.",
"     </li>",
"     <li>",
"      We suggest that the use of ECMO be considered in patients with a cardiac index &lt;2.5",
"      <span class=\"nowrap\">",
"       L/min/m2",
"      </span>",
"      despite the use of inotropic agents, in specialized centers where this technique is available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Extracorporeal membrane oxygenation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the limited treatment options and high mortality rates, emphasis needs to be on avoidance of exposure to potentially infectious rodents, particularly in indoor spaces. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/1\">",
"      Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. Emerg Infect Dis 1997; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/2\">",
"      Mertz GJ, Hjelle BL, Bryan RT. Hantavirus infection. Adv Intern Med 1997; 42:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of acute illness--southwestern United States, 1993. MMWR Morb Mortal Wkly Rep 1993; 42:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/4\">",
"      Jenison S, Hjelle B, Simpson S, et al. Hantavirus pulmonary syndrome: clinical, diagnostic, and virologic aspects. Semin Respir Infect 1995; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/5\">",
"      Lee HW, Lee PW, Johnson KM. Isolation of the etiologic agent of Korean Hemorrhagic fever. J Infect Dis 1978; 137:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/6\">",
"      Niklasson B, Le Duc J. Isolation of the nephropathia epidemica agent in Sweden. Lancet 1984; 1:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/7\">",
"      Zeitz PS, Butler JC, Cheek JE, et al. A case-control study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States. J Infect Dis 1995; 171:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/8\">",
"      Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/9\">",
"      Chizhikov VE, Spiropoulou CF, Morzunov SP, et al. Complete genetic characterization and analysis of isolation of Sin Nombre virus. J Virol 1995; 69:8132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/10\">",
"      Duchin JS, Koster FT, Peters CJ, et al. Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group. N Engl J Med 1994; 330:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/11\">",
"      Zaki SR, Khan AS, Goodman RA, et al. Retrospective diagnosis of hantavirus pulmonary syndrome, 1978-1993: implications for emerging infectious diseases. Arch Pathol Lab Med 1996; 120:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/12\">",
"      Frampton JW, Lanser S, Nichols CR. Sin Nombre virus infection in 1959. Lancet 1995; 346:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/13\">",
"      Hjelle B, Jenison S, Torrez-Martinez N, et al. A novel hantavirus associated with an outbreak of fatal respiratory disease in the southwestern United States: evolutionary relationships to known hantaviruses. J Virol 1994; 68:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/14\">",
"      Khan AS, Khabbaz RF, Armstrong LR, et al. Hantavirus pulmonary syndrome: the first 100 US cases. J Infect Dis 1996; 173:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Hantavirus pulmonary syndrome--five states, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: hantavirus pulmonary syndrome --- Maine, April 2011. MMWR Morb Mortal Wkly Rep 2011; 60:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/17\">",
"      Mertz GJ, Hjelle B, Crowley M, et al. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/18\">",
"      Doyle TJ, Bryan RT, Peters CJ. Viral hemorrhagic fevers and hantavirus infections in the Americas. Infect Dis Clin North Am 1998; 12:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/19\">",
"      Vincent MJ, Quiroz E, Gracia F, et al. Hantavirus pulmonary syndrome in Panama: identification of novel hantaviruses and their likely reservoirs. Virology 2000; 277:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/20\">",
"      Young JC, Hansen GR, Graves TK, et al. The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg 2000; 62:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/21\">",
"      Fritz CL, Young JC. Estimated incubation period for hantavirus pulmonary syndrome. Am J Trop Med Hyg 2001; 65:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/22\">",
"      Lee HW, van der Groen G. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/23\">",
"      Castillo C, Naranjo J, Sep&uacute;lveda A, et al. Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults. Chest 2001; 120:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/24\">",
"      Levy H, Simpson SQ. Hantavirus pulmonary syndrome. Am J Respir Crit Care Med 1994; 149:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/25\">",
"      Hallin GW, Simpson SQ, Crowell RE, et al. Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit Care Med 1996; 24:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/26\">",
"      Crowley MR, Katz RW, Kessler R, et al. Successful treatment of adults with severe Hantavirus pulmonary syndrome with extracorporeal membrane oxygenation. Crit Care Med 1998; 26:409.",
"     </a>",
"    </li>",
"    <li>",
"     Koster F, Hjelle B. The hantaviruses. In: Infectious Diseases, Gorbach JG, Bartlett JG, Blackow NR (Eds), WB Saunders Co., Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/28\">",
"      Passaro DJ, Shieh WJ, Hacker JK, et al. Predominant kidney involvement in a fatal case of hantavirus pulmonary syndrome caused by Sin Nombre virus. Clin Infect Dis 2001; 33:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/29\">",
"      Koster F, Foucar K, Hjelle B, et al. Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. Am J Clin Pathol 2001; 116:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/30\">",
"      Moolenaar RL, Dalton C, Lipman HB, et al. Clinical features that differentiate hantavirus pulmonary syndrome from three other acute respiratory illnesses. Clin Infect Dis 1995; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/31\">",
"      Chapman LE, Ellis BA, Koster FT, et al. Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis 2002; 34:293.",
"     </a>",
"    </li>",
"    <li>",
"     Mertz GJ, Hjelle B, Williams TM, Koster FT. Host responses in the hantavirus cardiopulmonary syndrome. In: Emergence and Control of Rodent-Borne Viral Diseases (Hantaviral and Arenal Diseases), Saluzzo JF, Dodet B (Eds), Elsevier, Paris 1999. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/33\">",
"      Hjelle B, Jenison S, Torrez-Martinez N, et al. Rapid and specific detection of Sin Nombre virus antibodies in patients with hantavirus pulmonary syndrome by a strip immunoblot assay suitable for field diagnosis. J Clin Microbiol 1997; 35:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/34\">",
"      Dietl CA, Wernly JA, Pett SB, et al. Extracorporeal membrane oxygenation support improves survival of patients with severe Hantavirus cardiopulmonary syndrome. J Thorac Cardiovasc Surg 2008; 135:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/35\">",
"      Sun Y, Chung DH, Chu YK, et al. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase. Antimicrob Agents Chemother 2007; 51:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/36\">",
"      Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/37\">",
"      Medina RA, Mirowsky-Garcia K, Hutt J, Hjelle B. Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J Gen Virol 2007; 88:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/38\">",
"      Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/39\">",
"      Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/40\">",
"      Medina RA, Mirowsky-Garcia K, Hutt J, Hjelle B. Ribavirin, human convalescent plasma and anti-beta3 integrin antibody inhibit infection by Sin Nombre virus in the deer mouse model. J Gen Virol 2007; 88:493.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/ncidod/diseases/hanta/hps/ (Accessed on September 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/42\">",
"      Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 1990; 64:3162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/43\">",
"      Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 1992; 47:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/44\">",
"      Bharadwaj M, Nofchissey R, Goade D, et al. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000; 182:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38119/abstract/45\">",
"      Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289:6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8321 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-C3CD4DCF74-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38119=[""].join("\n");
var outline_f37_14_38119=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL CASE DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prodrome/febrile phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiopulmonary phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oliguric and diuretic phases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Convalescent phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WHEN TO SUSPECT HANTAVIRUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antiviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vaccine development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13848?source=related_link\">",
"      Epidemiology and diagnosis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4920?source=related_link\">",
"      Pathogenesis of hantavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25544?source=related_link\">",
"      Renal involvement with hantavirus infection (hemorrhagic fever with renal syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38120="Hemodialysis anticoagulation";
var content_f37_14_38120=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodialysis anticoagulation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Eugene C Kovalik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38120/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/14/38120/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis and continuous renal replacement therapies require extracorporeal blood flow. Some form of anticoagulation, usually with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , is required to prevent thrombosis in the blood circuit. Strategies to minimize the risk of bleeding include low dose or \"minimum heparin\" as well as fast flow \"no heparin\" methods. Regional anticoagulation with citrate, prostacyclin, as well as heparin-protamine have also been used. The bleeding tendency induced by these regimens is additive to the commonly present platelet dysfunction associated with advanced renal failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=see_link\">",
"     \"Platelet dysfunction in uremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulation during hemodialysis can be monitored by the determination of activated clotting times (ACTs). However, although ACTs have advantages over whole blood clotting times in that they are interpreted by an automated method with rapid results, they are infrequently used because of quality assurance and regulatory issues.",
"   </p>",
"   <p>",
"    In general, most outpatient dialysis units do not routinely measure anticoagulation parameters unless there is an issue with dialyzer clotting or prolonged bleeding following dialysis. Usually each dialysis unit has a protocol that is followed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STANDARD ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation in routine hemodialysis consists of a standard dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    given as a bolus at the start of the dialysis treatment with a mid-treatment dose to maintain suitable anticoagulation. Alternatively, heparin modeling can be performed using an initial bolus followed by a constant fixed infusion of heparin to maintain an activated clotting time (ACT) of 200 to 250 seconds (normal = 90 to 140 seconds).",
"   </p>",
"   <p>",
"    The activated clotting time (activated whole blood clotting time or ACT) is performed by addition of an activating agent (eg, celite, kaolin) to a sample of freshly-drawn whole blood and measuring the time (in seconds) for formation of a clot. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical use of coagulation tests\", section on 'Activated whole blood clotting time'",
"    </a>",
"    .) This therapy ensures systemic anticoagulation throughout the dialysis treatment. It is reliable and requires minimal staff intervention after a patient's",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dose is determined (based on ACT goal).",
"   </p>",
"   <p>",
"    Some protocols use higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    doses with decreasing infusion rates as the treatment proceeds to minimize postdialysis bleeding from venipuncture sites. These methods require minimal staff intervention and are standard in most outpatient hemodialysis units; they are, however, unsuitable for patients with significant bleeding risks.",
"   </p>",
"   <p>",
"    Dialyzer clotting is a common factor underlying poor performance with dialyzer reuse, resulting in an enhanced frequency of discarded dialyzers. The adoption of an improved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing regimen with routine dialysis may increase the rate of reuse. In one study of 44 chronic hemodialysis patients, the use of a mathematical model system that determined the optimal heparin loading dose and infusion rate (to attain a whole-blood intradialytic clotting time of 150 percent of the predialysis level) significantly increased dialyzer reuse rates among the modeled, but not control, patient group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION IN HEMODIALYSIS PATIENTS AT RISK FOR BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of alternative modalities have been used in patients at high risk for bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     No heparin hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    hemodialysis was developed for use in the patient at high risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The protocol requires pretreating both the dialyzer and blood lines with 2000 to 5000 units of heparin contained in a liter of normal saline (",
"    <a class=\"graphic graphic_figure graphicRef56596 \" href=\"mobipreview.htm?14/21/14687\">",
"     figure 1",
"    </a>",
"    ). The heparinized saline is flushed from the extracorporeal lines prior to the start of the dialysis treatment so that heparin is not administered to the patient. Extracorporeal blood flows are rapidly increased to 250 to 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and maintained throughout the treatment, and 25 to 30 mL saline flushes are administered every 15 to 30 minutes into the arterial (pre-dialyzer) limb to minimize hemoconcentration and to wash fibrin strands from the kidney into the bubble trap. The volume of saline administered with such frequent flushing must be removed during the dialysis to prevent hypervolemia. One to one nursing is required with careful monitoring of the arterial and venous pressure alarms to detect early clotting.",
"   </p>",
"   <p>",
"    No",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    hemodialysis can be used in approximately 90 percent of intensive care unit patients with temporary venous access, with only a two percent clotting rate in the extracorporeal circuit. There is no significant loss of clearances compared to control patients treated with full anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/5\">",
"     5",
"    </a>",
"    ]. Disadvantages of this technique include the need for close nursing observation and the necessity to convert to minimum dose heparin or stop treatment in five percent of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood transfusions during no",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    hemodialysis require additional vascular access due to the increased risk of clotting in the dialyzer circuit. However, the availability of additional peripheral access is limited in some patients. In an attempt to overcome this problem, a technique based upon the insertion of a large bore stopcock permits the transfusion of blood into the venous outflow limb without significant difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Minimum dose heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of minimum dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been shown to reduce bleeding complications in high risk patients when compared to regional heparinization with protamine neutralization (10 percent versus 19 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/7\">",
"     7",
"    </a>",
"    ]. The protocol usually involves boluses of 500 units of heparin every 30 minutes to keep the activated clotting time &gt;150 but &lt;200 seconds (",
"    <a class=\"graphic graphic_figure graphicRef80980 \" href=\"mobipreview.htm?19/4/19535\">",
"     figure 2",
"    </a>",
"    ). Alternately, a continuous infusion of heparin with frequent ACT monitoring can be used to achieve the same degree of anticoagulation.",
"   </p>",
"   <p>",
"    The major advantage of this technique is that no additional equipment is needed in the dialysis circuit. The major disadvantage is that some minimal degree of anticoagulation of the patient still occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Regional anticoagulation with protamine reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest method described to reduce hemodialysis associated bleeding was regional anticoagulation with protamine reversal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. This procedure involves the constant infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    into the dialyzer inlet line and the simultaneous constant infusion of protamine prior to the blood returning to the patient (protamine binds to heparin and eliminates its anticoagulant activity) (",
"    <a class=\"graphic graphic_figure graphicRef74909 \" href=\"mobipreview.htm?32/22/33135\">",
"     figure 3",
"    </a>",
"    ). The infusion pump rates are adjusted to keep the whole blood activated clotting time in the dialyzer circuit at 250 seconds and the blood returning to the patient at its predialysis baseline. The protamine dosage to neutralize the heparin can be determined by the protamine titration test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protamine reversal has been largely abandoned due to its technical difficulties and to problems with rebound bleeding two to four hours after the end of dialysis as the reticuloendothelial system releases free",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    from the protamine-heparin complex back into the general circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition, simpler regimens consisting of minimum dose and no dose heparin as well as citrate regional anticoagulation have subsequently been developed that offer a lower incidence of bleeding complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Regional citrate anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regional citrate regimen that has been adopted in many institutions involves the continuous infusion of isosmotic trisodium citrate solution (102",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    into the arterial side of the dialyzer (",
"    <a class=\"graphic graphic_figure graphicRef67592 \" href=\"mobipreview.htm?3/54/3936\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/14\">",
"     14",
"    </a>",
"    ]. The fall in the free plasma calcium concentration induced by binding to citrate is responsible for the anticoagulant activity of this regimen by preventing the progression of the coagulation cascade. The citrate-calcium complex is removed across the dialyzer and a calcium free dialysate can also be used to further reduce the free calcium level in the blood. The citrate infusion rate is adjusted to keep the ACT above 200 seconds in the arterial limb.",
"   </p>",
"   <p>",
"    Regional anticoagulation is reversed by the infusion of five percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    into the venous return line at a rate of 0.5",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    This rate is constantly adjusted according to frequent measurements of plasma calcium concentration to prevent hypocalcemia or hypercalcemia. Several modifications of this technique have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative trials have shown a reduced incidence of bleeding with these regimens when compared to standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. The major problem with regional citrate anticoagulation are hypocalcemia or hypercalcemia, hypernatremia (due to the hypertonic sodium citrate solution), and metabolic alkalosis (due to bicarbonate generated during the metabolism of citrate) that may require hydrochloric acid infusion. If closely monitored, however, the complication rate is relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Specifically designed dialysate may also lower the incidence of electrolyte abnormalities, including metabolic alkalosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Citrate dialysate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of citric acid as the acid in dialysate concentrates has been described. Citric acid-based dialysates result in reduced clotting in no-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dialysis (by lowering serum calcium enough to interfere with the clotting cascade but not enough to cause symptomatic hypocalcemia) and increases patient bicarbonate levels (by the conversion of citrate to bicarbonate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The major disadvantage is that, at a citric acid concentration of 2.4",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    a small but significant change in serum calcium does occur, although usually not enough to cause symptoms. Further studies are needed to delineate the role of citric acid-based dialysates. It is commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prostacyclin regional anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The arachidonic metabolite prostacyclin is a vasodilator and inhibitor of platelet aggregation. Its in vitro half-life is 3 to 5 minutes due to rapid metabolism by endothelial smooth muscle. Prostacyclin regional anticoagulation involves the infusion of prostacyclin into the dialyzer circuit at 4 to 8",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/23\">",
"     23",
"    </a>",
"    ]. Side effects include headache, lightheadedness and facial flushing. However, its use has been limited by hypotension due to vasodilation and expense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nafamostat, a prostacyclin analog without the hypotensive activity, is not yet available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/25\">",
"     25",
"    </a>",
"    ]. It may, however, be associated with an unacceptably high incidence of clot formation. In one study using nafamostat, clot formation was observed in up to 36 percent of dialyzers despite adequate prolongation of the activated partial thromboplastin time (aPTT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, nafamostat cannot be used with polyacrylonitrile membranes due to adsorption onto the membrane surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional agents have been evaluated in hemodialysis patients at risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in current clinical use is polydispersed unmodified heparin (mean molecular weight ranging from 10,000 to 16,000 daltons). Low-molecular-weight (LMW) derivatives of commercial heparin have been prepared that have a mean molecular weight of 4000 to 5000 daltons. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .) Like unfractionated heparin, LMW heparins inactivate factor Xa, but they have a lesser effect on thrombin because most of the molecules do not contain enough saccharide units to bind to form the ternary complex in which thrombin and AT III are bound simultaneously.",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been proposed to cause less bleeding and less thrombocytopenia than heparin. However, these agents are very expensive and have generally not been found to be superior to heparin in terms of dialysis-related bleeding or other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/2\">",
"     2",
"    </a>",
"    ]. This is supported by the findings of a meta-analysis showing that LMW heparin and unfractionated heparin were similarly safe and effective in preventing extracorporeal circuit thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/27\">",
"     27",
"    </a>",
"    ]. The safety and efficacy of LMW heparin is also equivalent if administered via the arterial or venous route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized, crossover trial also found no benefit with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    compared to citrate in chronic hemodialysis patients at risk of bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/29\">",
"     29",
"    </a>",
"    ]. Unlike citrate, LMW heparin was found to induce systemic anticoagulation, although this effect was diminished by a divided dose regimen.",
"   </p>",
"   <p>",
"    An additional problem is that monitoring with the activated partial thromboplastin time (aPTT) is not accurate with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ; in this setting, measurement of heparinoid or anti-factor Xa levels provide a better indication of the degree of anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, once a patient develops",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT), LMW heparin",
"    <strong>",
"     cannot",
"    </strong>",
"    be used as a safe substitute. There is extensive crossreactivity (&gt;90 percent) between the LMW heparin and standard heparin in terms of antibody recognition, and the thrombocytopenia and hypercoagulable state may persist when a patient with immune-mediated thrombocytopenia is switched from standard heparin to LMW heparin. The main clinical concern in this disorder is a high incidence of thrombosis, not bleeding (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Heparin-induced thrombocytopenia'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recombinant hirudin anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirudin inhibits thrombin via the formation of a noncovalent complex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H3#H3\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Classification of anticoagulant agents'",
"    </a>",
"    .) Recombinant hirudin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    ) has been administered as a single bolus at the start of hemodialysis or as a continuous infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Lepirudin is an effective anticoagulant and may result in less prolongation of the ACT than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/32\">",
"     32",
"    </a>",
"    ]. However, its use has been limited because of a prolonged half-life in hemodialysis patients, possibly leading to bleeding complications with repetitive use.",
"   </p>",
"   <p>",
"    There is an ongoing clinical study that is assessing the safety of polyethylene glycol-hirudin compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . It is referred to as SPP200.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Heparin coated membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -coated dialysis membranes in patients at risk of bleeding was compared with regional citrate anticoagulation in a randomized controlled study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/34\">",
"     34",
"    </a>",
"    ]. The coated membranes were associated with a significantly increased incidence of membrane clotting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;No",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and regional citrate anticoagulation are associated with the lowest risks of bleeding and severe dialyzer clotting. The guidelines that we follow are summarized in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef53330 \" href=\"mobipreview.htm?12/4/12366\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CONTINUOUS HEMODIALYSIS MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is generally the preferred modality in continuous arteriovenous or venovenous hemofiltration or hemodialysis",
"    <span class=\"nowrap\">",
"     (CAVH/D",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     CVVH/D).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"     \"Continuous renal replacement therapies: Overview\"",
"    </a>",
"    .) The no heparin regimen is ineffective in this setting due to the low blood flow rates with these techniques and their continuous nature increases the likelihood of side effects with prostacyclin or protamine&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, a bolus dose of 1000 to 2000 units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is given initially followed by a continuous infusion into the arterial limb of the circuit of between 300 to 400 units",
"    <span class=\"nowrap\">",
"     heparin/hour",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef61990 \" href=\"mobipreview.htm?41/12/42189\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/36\">",
"     36",
"    </a>",
"    ]. The aim is to maintain the partial thromboplastin time in the venous limb at 1.5 to 2 times control. The heparin dose may be drastically reduced in patients with disseminated intravascular coagulation or thrombocytopenia. Unfortunately, there is some systemic anticoagulation with this technique and it may be contraindicated in patients at high risk of bleeding. The heparin dose and ACT goal can be adjusted downward in these patients, but with some increased risk of extracorporeal clotting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Regional citrate anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles and side effects of regional citrate anticoagulation in",
"    <span class=\"nowrap\">",
"     CAVD/D",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     CVVH/D",
"    </span>",
"    are the same as those in standard hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/36\">",
"     36",
"    </a>",
"    ]. The circuit in",
"    <span class=\"nowrap\">",
"     CAVVH/D",
"    </span>",
"    is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef75680 \" href=\"mobipreview.htm?12/30/12770\">",
"     figure 6",
"    </a>",
"    ); the circuit for",
"    <span class=\"nowrap\">",
"     CVVH/D",
"    </span>",
"    is similar to that for",
"    <span class=\"nowrap\">",
"     CAVVH/D",
"    </span>",
"    except only the venous lines are present with a blood pump interposed on the inflow side of the system.",
"   </p>",
"   <p>",
"    Despite",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    being the preferred modality, limited evidence suggests that regional citrate may improve the survival rate of hemofilters and lower bleeding risk compared with heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was found in a single center study of 30 patients undergoing continuous renal replacement therapy who were randomly assigned to regional citrate or systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulation (titrated to maintain a systemic PTT between 45 and 65 seconds) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/37\">",
"       37",
"      </a>",
"      ]. Citrate was significantly associated with longer hemofilter survival time (125 versus 38 hours) and decreased risk of hemorrhage (relative risk of 0.14, 95% CI of 0.02 to 0.96).",
"     </li>",
"     <li>",
"      In one multicentre study, 138 patients undergoing continuous renal replacement therapy were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or regional citrate anticoagulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/38\">",
"       38",
"      </a>",
"      ]. Life-threatening bleeding events were observed with heparin but not citrate, with no difference in circuit survival with the two anticoagulation methods.",
"     </li>",
"     <li>",
"      A meta-analysis of six randomized trials that compared citrate to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      anticoagulation among 488 patients (including 10 patients who received regional heparinization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/41\">",
"       41",
"      </a>",
"      ] and 200 patients who received low-molecular weight heparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/40\">",
"       40",
"      </a>",
"      ]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/42\">",
"       42",
"      </a>",
"      ]. Fewer patients in the citrate group had major bleeding events (relative risk 0.34, 95% CI 0.17-0.65) although there was no difference between groups in filter survival time, the incidence of metabolic alkalosis, and thrombocytopenia. Hypocalcemia was more common in the citrate group (relative risk 3.51, 95% CI 1.17-10.69), although no adverse events related to hypocalcemia were reported. Interpretation of this meta-analysis is limited by significant heterogeneity in citrate and heparin protocols used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study in a larger number of patients is required to more accurately define the relative benefits",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risks with these two approaches. Although citrate is, in general, slightly more complicated for nursing staff, appropriate protocols should simplify procedures.",
"   </p>",
"   <p>",
"    The potential complications (hypocalcemia, hypercalcemia, hypernatremia and metabolic alkalosis), although small in the above study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/37\">",
"     37",
"    </a>",
"    ], have generally made this regimen less desirable than minimal dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/37\">",
"     37",
"    </a>",
"    ]. The possibility of alkalosis may be lessened in part by using anticoagulant citrate dextrose formula a, which produces less bicarbonate compared with hypertonic trisodium citrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrate may over time become the preferred anticoagulation modality in continuous renal replacement therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Regional prostacyclin and LMW heparin anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the use of these anticoagulants with continuous dialytic techniques. One study found that prostacyclin decreased bleeding episodes in",
"    <span class=\"nowrap\">",
"     CAVH/D",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     CVVH/D",
"    </span>",
"    and was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in maintaining circuit integrity during",
"    <span class=\"nowrap\">",
"     CVVH/D",
"    </span>",
"    without inducing significant hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/45\">",
"     45",
"    </a>",
"    ]. Combinations of both prostacyclin and low molecular weight heparin have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/46\">",
"     46",
"    </a>",
"    ]. However, these favorable outcomes are at odds with studies performed during standard hemodialysis and must be interpreted with caution.",
"   </p>",
"   <p>",
"    Larger clinical trials with these agents are needed to establish their role in continuous renal replacement therapies. Current indications for the use of prostacyclin or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are similar to those in standard hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HEPARIN-INDUCED THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for patients who have developed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) include no heparin hemodialysis, regional citrate hemodialysis, a change to peritoneal dialysis, or the administration of one of the three drugs that appear to be effective in patients with HIT:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    , (which is a heparinoid and",
"    <strong>",
"     not",
"    </strong>",
"    a low molecular weight heparin), recombinant hirudin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Recombinant hirudin anticoagulation'",
"    </a>",
"    above), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited experience with these drugs in hemodialysis patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized three-way crossover study of 13 hemodialysis patients, the following three treatment regimens of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      were both safe and effective: (A) initial 250",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      bolus with an additional 250",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      bolus allowed after two hours; (B) initial 250",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      bolus, followed by 2",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min infusion, which was discontinued one hour before the end of the session; (C) steady state 2",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min infusion initiated four hours before dialysis and discontinued at the end of the session [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"       Danaparoid",
"      </a>",
"      has been given as a single dose of 34.4 anti-Xa",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      at the initiation of hemodialysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recombinant hirudin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"       lepirudin",
"      </a>",
"      ) has been given as an intravenous bolus at the initiation of dialysis or as a continuous infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Catheter lock issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis catheter lock options in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia are to pressure bag the catheters (which is impractical for outpatients) or to use either tissue plasminogen activator or urokinase. Highly concentrated (47 percent) citrate has also been used, but is not FDA approved due to issues of accidental systemic injection and arrhythmia. Studies with lower concentration citrate solution (4 to 7 percent) are currently under way. One study found that a 30 percent citrate solution was safe and also decreased the risk of catheter-related bacteremia as compared to a standard heparin locking solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given overall safety and reasonable ease of use, no",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    hemodialysis should be the first option among those with heparin-induced thrombocytopenia. If no heparin dialysis cannot be performed, the patient should be converted to peritoneal dialysis. The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"     danaparoid",
"    </a>",
"    appears to be a reasonable choice among those in whom no heparin hemodialysis and peritoneal dialysis are not feasible techniques. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review of various alternatives for anticoagulation in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia list the dosing guidelines for various agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38120/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3683741\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are on hemodialysis or continuous renal replacement therapies require anticoagulation to prevent thrombosis in the blood circuit. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation in routine hemodialysis consists of a standard dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      given as a bolus at the start of the dialysis treatment with a mid-treatment dose to maintain suitable anticoagulation. Alternatively, heparin modeling can be performed using an initial bolus followed by a constant fixed infusion of heparin to maintain an activated clotting time (ACT) of 200 to 250 seconds. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Standard anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Options for patients on hemodialysis who are at high risk for bleeding include no",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      hemodialysis, minimum dose heparin, regional anticoagulation with protamine reversal, regional citrate anticoagulation, citrate dialysate, and prostacyclin regional anticoagulation. No heparin and regional citrate anticoagulation are associated with the lowest risks of bleeding and severe dialyzer clotting. Protamine reversal has been largely abandoned due to its technical difficulties and to problems with rebound bleeding. &nbsp; &nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anticoagulation in hemodialysis patients at risk for bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minimal dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is generally the preferred modality in continuous arteriovenous or venovenous hemofiltration or hemodialysis",
"      <span class=\"nowrap\">",
"       (CAVH/D",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       CVVH/D).",
"      </span>",
"      Typically, a bolus dose of 1000 to 2000 units of heparin is given initially followed by a continuous infusion into the arterial limb of the circuit of between 300 to 400 units",
"      <span class=\"nowrap\">",
"       heparin/hour",
"      </span>",
"      with a goal to maintain the partial thromboplastin time in the venous limb at 1.5 to 2 times control. There is some systemic anticoagulation associated with this technique and it may be contraindicated in patients at high risk of bleeding. The no heparin regimen is ineffective in this setting due to the low blood flow rates (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Continuous hemodialysis modalities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=see_link\">",
"       \"Continuous renal replacement therapies: Overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Options for patients who have developed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia (HIT) include no heparin hemodialysis, regional citrate hemodialysis, a change to peritoneal dialysis, or the administration of either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/18/41254?source=see_link\">",
"       danaparoid",
"      </a>",
"      , (which is a heparinoid and",
"      <strong>",
"       not",
"      </strong>",
"      a low molecular weight heparin), or recombinant hirudin (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/45/4823?source=see_link\">",
"       lepirudin",
"      </a>",
"      ). The preferred option for patients with heparin-induced thrombocytopenia is no heparin hemodialysis. If no heparin dialysis cannot be performed, the patient should be converted to peritoneal dialysis (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Heparin-induced thrombocytopenia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"       \"Anticoagulants other than heparin and warfarin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodialysis catheter lock options in patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia are to pressure bag the catheters (which is impractical for outpatients) or to use either tissue plasminogen activator or urokinase. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Catheter lock issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/1\">",
"      Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis 2000; 35:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/2\">",
"      Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/3\">",
"      Sanders PW, Taylor H, Curtis JJ. Hemodialysis without anticoagulation. Am J Kidney Dis 1985; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/4\">",
"      Stamatiadis DN, Helioti H, Mansour M, et al. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol 2004; 62:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/5\">",
"      Schwab SJ, Onorato JJ, Sharar LR, Dennis PA. Hemodialysis without anticoagulation. One-year prospective trial in hospitalized patients at risk for bleeding. Am J Med 1987; 83:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/6\">",
"      Sepulveda S, Davis L, Schwab SJ. Blood transfusion during heparin-free hemodialysis. Kidney Int 1997; 51:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/7\">",
"      Swartz RD, Port FK. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int 1979; 16:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/8\">",
"      GORDON LA, PERKINS HA, RICHARDS V, et al. Studies in regional heparinization. II. Artificial-kidney hemodialysis without systemic heparinization; preliminary report of a method using simultaneous infusion of heparin and protamine. N Engl J Med 1956; 255:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/9\">",
"      Maher, JF, Lapierre, L, Schreiner, GE, et al. Regional heparinization for hemodialysis. N Engl J Med 1963; 268:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/10\">",
"      Lindholm DD, Murray JS. A simplified method of regional heparinization during hemodialysis according to a predetermined dosage formula. Trans Am Soc Artif Intern Organs 1964; 10:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/11\">",
"      Spencer, P, Cozzi, E, Easterling, RE, Penner, JA. Regional Heparinization with the Hollow Fiber Artificial Kidney. Proc Am Assoc Nephrol Nurses Technicians 1977; 4:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/12\">",
"      Congdon JE, Kardinal CG, Wallin JD. Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests. JAMA 1973; 226:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/13\">",
"      Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. Trans Am Soc Artif Intern Organs 1966; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/14\">",
"      Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/15\">",
"      von Brecht JH, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/16\">",
"      Janssen MJ, Huijgens PC, Bouman AA, et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993; 8:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/17\">",
"      Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/18\">",
"      Apsner R, Buchmayer H, Lang T, et al. Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kidney Dis 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/19\">",
"      Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G. Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis 2005; 45:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/20\">",
"      Morgera,S, Haase, M, Ruckert, M, et al. Regional citrate anticoagulation in continuous hemodialysis-acid-base and electrolyte balance at an increased dose of dialysis. Nephrol Clin Pract 2005; 101:C211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/21\">",
"      Ahmad S, Callan R, Cole JJ, Blagg CR. Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 2000; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/22\">",
"      Tu, A, Ahmad, S. Heparin-free hemodialysis with citrate-containing dialysate in intensive care patients. Dial Transplant 2000; 29:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/23\">",
"      Swartz RD, Flamenbaum W, Dubrow A, et al. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J Clin Pharmacol 1988; 28:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/24\">",
"      Caruana RJ, Smith MC, Clyne D, et al. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif 1991; 9:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/25\">",
"      Ota K, Kawaguchi H, Takahashi K, Ito K. A new prostacyclin analogue - an anticoagulant applicable to hemodialysis. Trans Am Soc Artif Intern Organs 1983; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/26\">",
"      Matsuo T, Kario K, Nakao K, et al. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/27\">",
"      Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15:3192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/28\">",
"      Vanuytsel JL, Lins RL, Zach&eacute;e P, et al. Comparison of different routes of administration of nadroparin in hemodialysis. Clin Nephrol 1999; 52:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/29\">",
"      Janssen MJ, Deegens JK, Kapinga TH, et al. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996; 49:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/30\">",
"      Schrader J, Stibbe W, Kandt M, et al. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. ASAIO Trans 1990; 36:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/31\">",
"      Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis 2002; 40:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/32\">",
"      van Wyk V, Badenhorst PN, Luus HG, Kotz&eacute; HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/33\">",
"      Fischer KG, van de Loo A, B&ouml;hler J. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl 1999; :S46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/34\">",
"      Evenepoel P, Dejagere T, Verhamme P, et al. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 2007; 49:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/35\">",
"      Ward DM. The approach to anticoagulation in patients treated with extracorporeal therapy in the intensive care unit. Adv Ren Replace Ther 1997; 4:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/36\">",
"      Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/37\">",
"      Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/38\">",
"      Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005; 20:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/39\">",
"      Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/40\">",
"      Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/41\">",
"      Fealy N, Baldwin I, Johnstone M, et al. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs 2007; 30:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/42\">",
"      Wu MY, Hsu YH, Bai CH, et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/43\">",
"      Tolwani A, Wille KM. Regional citrate anticoagulation for continuous renal replacement therapy: the better alternative? Am J Kidney Dis 2012; 59:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/44\">",
"      Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis 2004; 43:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/45\">",
"      Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/46\">",
"      Journois D, Chanu D, Pouard P, et al. Assessment of standardized ultrafiltrate production rate using prostacyclin in continuous venovenous hemofiltration. Contrib Nephrol 1991; 93:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/47\">",
"      European best practice guidelines for haemodialysis (Part 1). Nephrol Dial Transplant 2002; 17(Suppl 7):25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/48\">",
"      Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004; 66:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/49\">",
"      Henny CP, ten Cate H, Surachno S, et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 1985; 54:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/50\">",
"      Weijmer, MC, Van den Dorpel, MA, Van de Ven, PG, et al. Randomized, clinical trial comparison of Trisodium citrate 30 percent and heparin as catheter-locking solution in hemodialysis patients. Am J Kidney Dis 2005; 2769:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38120/abstract/51\">",
"      O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003; 16:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1840 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38120=[""].join("\n");
var outline_f37_14_38120=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3683741\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STANDARD ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTICOAGULATION IN HEMODIALYSIS PATIENTS AT RISK FOR BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      No heparin hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Minimum dose heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Regional anticoagulation with protamine reversal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Regional citrate anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Citrate dialysate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prostacyclin regional anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recombinant hirudin anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Heparin coated membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CONTINUOUS HEMODIALYSIS MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Regional citrate anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Regional prostacyclin and LMW heparin anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HEPARIN-INDUCED THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Catheter lock issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3683741\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1840|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/4/12366\" title=\"algorithm 1\">",
"      Anticoagulation algorithm in HD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1840|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/21/14687\" title=\"figure 1\">",
"      No heparin regimen in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/4/19535\" title=\"figure 2\">",
"      Minimum dose heparin in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/22/33135\" title=\"figure 3\">",
"      Protamine reversal in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/54/3936\" title=\"figure 4\">",
"      Regional citrate in HD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/12/42189\" title=\"figure 5\">",
"      Minimum heparin in CAVHF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/30/12770\" title=\"figure 6\">",
"      Circuitry of CAVHD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38516?source=related_link\">",
"      Continuous renal replacement therapies: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38121="Pheochromocytoma in children";
var content_f37_14_38121=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pheochromocytoma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/14/38121/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/14/38121/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas and paragangliomas are rare neoplasms in children. Tumors that arise from the adrenal medulla are termed pheochromocytomas, and those with extra-adrenal origins are called paragangliomas. Among hypertensive children, the incidence of surgically confirmed disease has ranged from 0.8 to 1.7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Because of the uncommon nature of the disease, few published reports document more than 15 cases even during prolonged observation periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Given the limited experience with pheochromocytomas in children and the similarity in clinical presentation, diagnosis, and treatment among children and adults, the following discussion includes some data derived from the adult literature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of pheochromocytomas and paragangliomas are caused by tumoral hypersecretion of norepinephrine, epinephrine, and dopamine, although increased central sympathetic activity also may contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7\">",
"     7",
"    </a>",
"    ]. The classic triad of symptoms in these disorders consists of episodic headache, sweating, and tachycardia, usually accompanied by hypertension. However, only 50 percent of adult patients have one or more of the \"three classic symptoms\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/8\">",
"     8",
"    </a>",
"    ]. Symptoms caused by the mass effect of the tumor, such as abdominal pain and distension or back pain, were found in 30 percent of children in one study; 64 percent of the patients had hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6\">",
"     6",
"    </a>",
"    ]. Most children have sustained hypertension rather than paroxysmal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Malignant hypertension can occur with its associated complications (eg, increased intracranial pressure, encephalopathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other signs and symptoms that occur less frequently include pallor, orthostatic hypotension (which may reflect a low plasma volume), constipation, psychiatric disorders, blurred vision, weight loss, polyuria, polydipsia, increased erythrocyte sedimentation rate, hyperglycemia, and a dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,7,12\">",
"     1,7,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation is often different when pheochromocytoma is associated with the multiple endocrine neoplasia type 2 (MEN2) syndrome. Symptoms are present in only approximately one-half of patients, and only one-third have hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/13\">",
"     13",
"    </a>",
"    ]. Whether this difference is due to ascertainment bias from screening for pheochromocytomas in families with MEN2 or a real difference in the clinical expression of the disease is not known. A similar finding has been observed with pheochromocytoma associated with von Hippel-Lindau (VHL) disease, as 35 percent of patients have no symptoms, a normal blood pressure, and normal catecholamine tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to adults, children with pheochromocytomas have a higher incidence of bilateral adrenal tumors, extraadrenal tumors, and multiple tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,4,15\">",
"     1,4,15",
"    </a>",
"    ]. In different series, extraadrenal tumors have been described in 30 to 60 percent of children (contrasted to 10 to 15 percent of adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6,9,16,17\">",
"     6,9,16,17",
"    </a>",
"    ], and multiple tumors have been described in up to 40 percent (compared to 5 to 10 percent in adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/18\">",
"     18",
"    </a>",
"    ]. Multicentric disease is more common with familial disorders such as MEN2 and mutations in succinate dehydrogenase (SDH; succinate:ubiquinone oxidoreductase) and subunit genes (SDHB, SDHC, SDHD, SDHAF2, SDHA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Catecholamine-secreting paragangliomas are co-located with chromaffin tissues (eg, along the para-aortic sympathetic chain, within the organs of Zuckerkandl at the origin of the inferior mesenteric artery, wall of the urinary bladder, and the sympathetic chain in the neck or mediastinum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children and adolescents with pheochromocytoma or paraganglioma are at risk for malignant disease. Approximately 10 percent of pheochromocytomas in adults are malignant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7,23\">",
"     7,23",
"    </a>",
"    ], whereas up to 47 percent of children in one series had malignant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6\">",
"     6",
"    </a>",
"    ]. In a series of 30 children with either pheochromocytoma or paraganglioma, statistically significant risk factors for malignancy included paraganglioma, apparent sporadic disease, and tumor size greater than 6 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignant pheochromocytomas and paragangliomas are histologically and biochemically the same as benign tumors. Thus, the only clue to the presence of a malignant pheochromocytoma is regional invasion or distant metastases, which may occur as long as 20 more years after resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF SYMPATHETIC OVERACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathetic activity is increased in several conditions other than pheochromocytoma. The two main causes in children are sympathomimetic drug ingestion and panic disorder.",
"   </p>",
"   <p>",
"    Sympathomimetic drugs that can induce symptoms simulating pheochromocytoma include high-dose phenylpropanolamine (a popular over-the-counter decongestant and appetite suppressant), cocaine, amphetamines, phencyclidine, epinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/46/41696?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/51/25397?source=see_link\">",
"     terbutaline",
"    </a>",
"    , and the combination of a monoamine oxidase (MAO) inhibitor and ingestion of tyramine-containing foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7,25-28\">",
"     7,25-28",
"    </a>",
"    ]. Mercury intoxication also can mimic pheochromocytoma, producing both hypertension and elevated urine and plasma catecholamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Panic disorder can replicate many of the symptoms of pheochromocytoma because it is associated with increased sympathetic activity. Hypertension in these patients occurs primarily during treatment with a tricyclic antidepressant drug, which may increase the degree of sympathetic arousal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although uncommon, panic disorder does occur in children, primarily adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The potential importance of this disorder in the differential diagnosis of pheochromocytoma was illustrated in a study in which 300 adults were referred for possible pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/33\">",
"     33",
"    </a>",
"    ]. Only one had the disease but 40 percent met the criteria for panic disorder, compared with 5 percent of control patients with hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHEOCHROMOCYTOMA IN GENETIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pheochromocytomas are sporadic. In adults, 10 to 20 percent of pheochromocytomas are familial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/34\">",
"     34",
"    </a>",
"    ], but there appears to be a higher proportion of the familial type in children. In three series with a total of 68 children, 22 (32 percent) had familial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6,10,22\">",
"     6,10,22",
"    </a>",
"    ]. As compared to the sporadic type, familial adrenal pheochromocytomas are more likely to be bilateral; familial paragangliomas are more likely to be multicentric. The molecular genetics of these disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial pheochromocytoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The familial syndromes associated with pheochromocytoma have autosomal dominant inheritance.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multiple endocrine neoplasia type 2A",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 2B",
"     </li>",
"     <li>",
"      von Hippel-Lindau (VHL) disease",
"     </li>",
"     <li>",
"      Neurofibromatosis type 1 (NF1)",
"     </li>",
"     <li>",
"      Succinate dehydrogenase (SDH; succinate:ubiquinone oxidoreductase) subunit genes (SDHB, SDHC, SDHD, SDHAF2, SDHA)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FP/TMEM127",
"      </span>",
"      gene mutations",
"     </li>",
"     <li>",
"      MAX gene mutations",
"     </li>",
"     <li>",
"      KIF1B, and EGLN1 gene mutations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These syndromes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"     \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 50 percent of cases of multiple endocrine neoplasia include pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/35\">",
"     35",
"    </a>",
"    ]. Between 10 and 20 percent of cases of VHL disease include pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/35\">",
"     35",
"    </a>",
"    ]. Approximately 2 percent of patients with a disease-associated NF1 mutation develop catecholamine-secreting tumors, which may be adrenal pheochromocytomas or abdominal paragangliomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catecholamine-secreting tumors may be associated with other neurocutaneous syndromes, including ataxia-telangiectasia, tuberous sclerosis, and Sturge-Weber syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Familial paraganglioma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial paraganglioma is an autosomal dominant disorder characterized by paragangliomas that are located most often in the head and neck but also in the thorax, abdomen, pelvis, and urinary bladder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link&amp;anchor=H5#H5\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Familial paraganglioma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Non-familial syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytomas and paragangliomas also are associated with syndromes that do not appear to have a familial basis. These include cholelithiasis, renal artery stenosis, and Carney's syndrome or triad (gastrointestinal stromal tumor [GIST], pulmonary chondromas, paraganglioma, adrenal cortical adenoma, and esophageal leiomyoma). The clinical features of these disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link&amp;anchor=H1013925#H1013925\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Pediatric GIST'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sporadic tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in patients with apparently sporadic pheochromocytomas, up to 25 percent will have unsuspected germline mutations of the RET, VHL, SDHD, SDHB, SHDC, SDHAF2, SDHA, TMEM127, or MAX genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/37\">",
"     37",
"    </a>",
"    ]. Genetic testing of these patients may identify individuals and families at risk for other associated tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link&amp;anchor=H6#H6\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Sporadic pheochromocytoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequence of diagnostic testing depends on the clinical presentation of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patients with symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child presenting with clinical symptoms suggestive of pheochromocytoma, such as severe hypertension, should undergo biochemical testing for pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=see_link\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\"",
"    </a>",
"    .) The presence of papilledema, hematuria, focal neurologic deficits, or unrelenting headache further support the possibility of pheochromocytoma, and warrant diagnostic evaluation for this and other causes of intracranial hypertension. The most appropriate initial diagnostic assay for pheochromocytoma is measurement of fractionated metanephrines and catecholamines in a 24-hour urine collection or plasma fractionated metanephrines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Biochemical testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Patients with family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;An asymptomatic person at risk for disease on the basis of family history of",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma,",
"    </span>",
"    MEN-2, von Hippel-Lindau disease, or familial paraganglioma should have genetic testing if an affected family member has a known mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Genetic testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"     \"Pheochromocytoma in genetic disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients with known mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;An asymptomatic person with a known mutation associated with the familial",
"    <span class=\"nowrap\">",
"     pheochromocytoma/paraganglioma",
"    </span>",
"    syndromes (ie, mutations in the VHL, RET, SDHB, SDHD, SDHC, SDHAF2, SDHA, TMEM127, or MAX genes) should have periodic evaluation for the development of pheochromocytoma as well as other associated tumors. Biochemical testing and blood pressure measurements should be performed annually beginning at age five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Because these patients are at high risk for pheochromocytoma, plasma fractionated metanephrines is the preferred case-detection test as compared to urinary fractionated metanephrines and catecholamines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H15\">",
"     'Biochemical testing'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8872?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Screening for pheochromocytoma and hyperparathyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because patients with SDHx mutations may have biochemically silent paragangliomas, periodic imaging is indicated. Patients with SDHC and SDHAF2 mutations should have neck imaging (ultrasound or MRI) every three years and periodic abdominal imaging because of the rare association with abdominal paraganglioma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with SDHD and SDHB mutations should have neck imaging (ultrasound or MRI) every three years, abdominal imaging (CT or MRI) every three years, and total body imaging with 123-I-MIBG scintigraphy every five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with germline mutations that predispose to the development of pheochromocytoma or paraganglioma are typically not diagnosed until adulthood, onset during childhood can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. A genetic cause should be sought in all children with pheochromocytoma or paraganglioma.",
"   </p>",
"   <p>",
"    Genetic testing can be complex. Testing one family member has implications for related individuals. Genetic counseling is recommended to help families understand the implications of genetic test results, to coordinate testing of at-risk individuals, and to help families work through the psychosocial issues that may arise before, during, or after the testing process.",
"   </p>",
"   <p>",
"    The clinician may obtain a list of clinically approved molecular genetic diagnostic laboratories at",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    . Given the considerable cost of genetic testing, using a stepwise approach based on each patient's clinical scenario is prudent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/43\">",
"     43",
"    </a>",
"    ]. This stepwise approach, and other details related to genetic testing, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link&amp;anchor=H7#H7\">",
"     \"Pheochromocytoma in genetic disorders\", section on 'Genetic screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Biochemical testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pheochromocytoma is usually suggested by the history in a symptomatic patient or the family history in a patient with familial disease. The diagnosis in the pediatric age group is best confirmed by measurement of 24-hour fractionated urinary metanephrines and catecholamines followed by radiographic localization of the tumor. In young children in whom an accurate 24-hour urine collection is not possible, measurement of plasma fractionated metanephrines is a reasonable alternative initial test. Most of the larger studies of the accuracy of the individual tests have been performed in adults with pheochromocytoma; as a result, some of these data are included in this section. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Diagnostic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurements of plasma or urine catecholamines and metabolites are highly sensitive and specific in patients with symptoms (sensitivity = 98 percent, specificity = 98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,12,40,44,45\">",
"     1,12,40,44,45",
"    </a>",
"    ]. All patients with symptomatic pheochromocytoma have clearly abnormal values for any of these tests. However, normotensive and asymptomatic patients may have normal or mildly abnormal values. Thus, when a test result is equivocal, a different test should be done. A variety of drugs can interfere with these tests and should ideally be stopped prior to testing (",
"    <a class=\"graphic graphic_table graphicRef80180 \" href=\"mobipreview.htm?3/38/3691\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Interfering medications'",
"    </a>",
"    .) Measurements of fractionated metanephrines and catecholamines should be performed in reference laboratories that employ high performance liquid chromatography (HPLC) or tandem mass spectrometry technology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Urinary fractionated metanephrines and catecholamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with pheochromocytoma have increased urinary excretion of fractionated metanephrines and free catecholamines (norepinephrine, epinephrine, and dopamine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7,25,45\">",
"     7,25,45",
"    </a>",
"    ]. In general, large tumors produce more metanephrines because the catecholamines are metabolized within the tumor before they are released, whereas small tumors are more likely to release free catecholamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7\">",
"     7",
"    </a>",
"    ]. Urinary fractionated metanephrine excretion and catecholamine secretion decrease from the newborn period and adolescence, and then do not change as a function of age or sex in normal subjects from adolescence to adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adolescents and adults, 24-hour urinary measurement of fractionated metanephrines and catecholamines is the most useful case detection test because of its combined sensitivity and specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/45\">",
"     45",
"    </a>",
"    ]. The diagnostic cutoffs for these assays tend to cause some false-positive testing, because they are usually based on normal ranges derived from a reference group of healthy normotensive volunteers. As an example, in normotensive volunteers, the 95th percentiles are 428 mcg for normetanephrine and 200 mcg for metanephrine, whereas in individuals being tested for pheochromocytoma (but who do not have the neoplasm), the 95th percentiles are 71 percent and 51 percent higher than these values, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 24-hour urine sample is usually collected for measurements of fractionated urinary metanephrines and catecholamines in stable patients; the urinary creatinine should also be measured in the sample to verify an adequate collection. However, an overnight urine collection may be accurate and more convenient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/48\">",
"     48",
"    </a>",
"    ]. Shorter collections (&lt;24 hours) are more likely to yield false-positive results because of various acute events associated with sympathetic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Plasma fractionated metanephrines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma fractionated metanephrines are a product of intra-pheochromocytoma catecholamine metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/48,50,51\">",
"     48,50,51",
"    </a>",
"    ]. Measurement of plasma fractionated metanephrines is a more sensitive assay than measurement of plasma catecholamines in children because it does not depend upon the frequently erratic secretion of epinephrine and norepinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/50,52\">",
"     50,52",
"    </a>",
"    ]. However, the increased sensitivity comes at the expense of a suboptimal false-positive rate of 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/53\">",
"     53",
"    </a>",
"    ]. Nevertheless, in children in whom 24-hour urinary collections may be inaccurate, plasma fractionated metanephrines are the best test currently available. In high-risk patients, such as those with known mutations for familial pheochromocytomas, plasma fractionated metanephrines is the test of choice because of its higher sensitivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Plasma fractionated metanephrines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of fractionated catecholamines in plasma is not useful in the diagnostic evaluation of the child or adolescent for possible pheochromocytoma because of high false-positive rates. The tests discussed above (plasma fractionated metanephrines, 24-hour urinary fractionated metanephrines and catecholamines) are superior.",
"   </p>",
"   <p>",
"    Other tests have been used in adults when the above tests are not diagnostic and the clinical circumstances remain suggestive, such as the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    suppression test, serum chromogranin A, and the",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/0/37891?source=see_link\">",
"     glucagon",
"    </a>",
"    stimulation test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7,54-57\">",
"     7,54-57",
"    </a>",
"    ]. However, due to the superior test characteristics of plasma and urinary fractionated metanephrines, these other tests are rarely used in adults and have not been validated in studies of children with suspected pheochromocytomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1,3,34\">",
"     1,3,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Radiologic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal urine or serum test results should be followed by radiological evaluation to locate the tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7,25\">",
"     7,25",
"    </a>",
"    ]. As noted above, 30 to 60 percent of these tumors in children are extraadrenal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6,9,16,17\">",
"     6,9,16,17",
"    </a>",
"    ]. Although any site containing paraganglionic tissue may be involved, the most common extraadrenal locations in one review were the superior and inferior para-aortic areas (75 percent of extraadrenal tumors); the bladder (10 percent); the thorax (10 percent); and the skull base, neck, and pelvis (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis is usually performed first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. Either test detects almost all sporadic tumors because most symptomatic neoplasms are 3 cm or larger in diameter. In a selected group of adults with a 40 percent incidence of pheochromocytoma, the respective positive and negative predictive values of CT were 69 and 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7\">",
"     7",
"    </a>",
"    ]. The false-positive tests were largely caused by adrenal \"incidentalomas\" (an incidental finding on imaging unrelated to the clinical problem) that are not a major issue in children.",
"   </p>",
"   <p>",
"    The choice between CT and MRI depends upon the cost and certain other factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With CT, there is some exposure to radiation and contrast dye is used [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With MRI, neither radiation nor dye is used. This more expensive test can distinguish pheochromocytoma from other adrenal masses; on T2-weighted images, pheochromocytomas appear hyperintense and other adrenal tumors hypointense, as compared with the liver (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56897 \" href=\"mobipreview.htm?37/31/38385\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If CT or MRI is negative in the presence of clinical and biochemical evidence of pheochromocytoma, then 123-I-metaiodobenzylguanidine (MIBG) or 111-In-pentetreotide (Octreoscan) imaging may be done. The former is a compound resembling norepinephrine that is taken up by adrenergic tissue, and the latter is taken up by tissues rich in somatostatin receptors (which includes adrenergic tissue). Scintigraphy using 123-I-MIBG can detect tumors not detected by abdominal CT or MRI, extraadrenal tumors not seen on abdominal imaging, metastatic disease, or multiple tumors when CT or MRI is positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7\">",
"     7",
"    </a>",
"    ]. Multiple tumors are found in up to 40 percent of children, particularly those with extraadrenal tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/16,18\">",
"     16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these observations, some clinicians have suggested that 123-I-MIBG scintigraphy be performed in all children with pheochromocytomas, even if the CT scan is positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/9\">",
"     9",
"    </a>",
"    ]. However, 123-I-MIBG scintigraphy has identified apparent extraadrenal \"tumors\" that were not confirmed at surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, most clinicians with experience with these patients find that it does not add to the clinical management of patients with solitary adrenal pheochromocytoma identified by CT or MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. In one series, the addition of single-photon emission computerized tomography (SPECT) technique to the 123-I-MIBG scintigraphy contributed to the evaluation of several patients for whom the diagnostic CT was equivocal, particularly when the interpretation of the CT was complicated by anatomic distortion after surgery or irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/62\">",
"     62",
"    </a>",
"    ]. The sensitivity of 111-In-pentetreotide imaging is comparable to that of 123-I-MIBG. Rarely, 111-In-pentetreotide will detect a tumor in an unusual location (eg, the heart) when the other techniques have failed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positron emission tomography (PET)-scanning with 18F-fluorodeoxyglucose or 11C-hydroxyephedrine or 6-[18F]fluorodopamine may be helpful in identifying sites of metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/51,64,65\">",
"     51,64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\", section on 'Other imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Selective adrenal venous sampling has been used in the past, but has led to inappropriate adrenalectomy. With advances in computerized imaging and the recognition that symptomatic catecholamine-secreting tumors are typically more than 3.5 cm in diameter, it is clear that radiographic methods are sensitive. Thus, venous sampling tests are superfluous and potentially misleading because there can be up to an 82-fold difference in catecholamine concentrations between the right and left adrenal veins in individuals without pheochromocytoma. Thus, adrenal venous sampling in search of pheochromocytoma should never be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/58,59,66,67\">",
"     58,59,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a pheochromocytoma is diagnosed, the patient should undergo surgery after appropriate medical preparation. Preoperative resolution of symptoms and normalization of blood pressure are predictors of an uncomplicated outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Medical preparation for surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;No universally accepted method of preparation for surgery in children with pheochromocytomas has been established. In our practice we generally use alpha-adrenergic blockade with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19364?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    (Dibenzyline) unless contraindicated because of cardiopulmonary concerns. The starting dose of phenoxybenzamine in children is 0.25 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or 10 mg once daily; the dose is increased every few days until the patient's symptoms and blood pressure are controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the second or third day of alpha-adrenergic blockade, patients are encouraged to start a diet high in sodium content because of the catecholamine-induced volume contraction and the orthostasis associated with alpha-adrenergic blockade. This causes intravascular volume expansion, which may be contraindicated in patients with heart failure or renal insufficiency.",
"   </p>",
"   <p>",
"    After adequate alpha-adrenergic blockade has been achieved, beta-adrenergic blockade is initiated, which typically occurs two to three days preoperatively. The beta-adrenergic blocker should",
"    <strong>",
"     never",
"    </strong>",
"    be started first, because blockade of vasodilatory peripheral beta-adrenergic receptors with unopposed alpha-adrenergic receptor stimulation can lead to a further elevation in blood pressure. The clinician should exercise caution if the patient is asthmatic or has heart failure. Chronic catecholamine excess can produce a cardiomyopathy that may become evident with the initiation of beta-adrenergic blockade, resulting in acute pulmonary edema. Therefore, when the beta-adrenergic blocker is administered, it should be used cautiously and at a low dose. The dose is then increased as necessary to control the tachycardia. In most cases, the patient is ready for surgery in 10 to 14 days after starting the alpha-adrenergic blockade.",
"   </p>",
"   <p>",
"    Although perioperative alpha blockade is widely recommended, a second regimen that has been utilized in adults at the Cleveland Clinic and France involves the administration of a calcium channel blocker for blood pressure control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In a review of 113 adult patients who underwent removal of pheochromocytomas, fewer perioperative complications were observed in those not given alpha-adrenergic antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Calcium channel blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A third approach is to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    (alpha-methyl-para-tyrosine), which inhibits catecholamine synthesis by blocking the enzyme tyrosine hydroxylase. Metyrosine should be used with caution and only when other agents have been ineffective or if significant tumor manipulation is anticipated. Although some centers have used this agent routinely, most clinicians reserve metyrosine primarily for patients who cannot be treated with the combined alpha and beta-adrenergic blockade protocol because of intolerance or cardiopulmonary concerns. The starting dose of metyrosine in children is 125 mg (250 capsules can be reduced to 125 mg capsules by a pharmacist) once or twice daily, with an increase in dose as required or based on a target decline in fractionated metanephrines and catecholamines (unpublished personal experience). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Metyrosine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of pheochromocytomas in children usually results in the restoration of normal blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/3,9,22\">",
"     3,9,22",
"    </a>",
"    ] unless a remaining tumor is present. The late return of hypertension frequently signals recurrent disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. With removal of all tumor tissue, catecholamine secretion and the blood pressure should fall to normal levels within one week.",
"   </p>",
"   <p>",
"    Laparoscopic surgery may be performed in patients with unilateral or bilateral adrenal pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Paragangliomas usually require an open surgical approach.",
"   </p>",
"   <p>",
"    When bilateral adrenal pheochromocytomas are present, as sometimes occurs in patients with von Hippel-Lindau disease or MEN2, bilateral total laparoscopic adrenalectomy is usually performed. It may be possible to preserve part of the adrenal cortex in some of these patients by either open or laparoscopic surgery, thereby avoiding permanent adrenal insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. The risk of this approach is recurrent pheochromocytoma, which occurred in 3 of 14 patients (21 percent) in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/76\">",
"     76",
"    </a>",
"    ]. Familial pheochromocytoma patients with unilateral disease should be treated with unilateral adrenalectomy, even though they are at risk for recurrence in the contralateral gland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8872?source=see_link&amp;anchor=H8#H8\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\", section on 'Pheochromocytoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral total adrenalectomy also has been recommended for childhood familial pheochromocytomas because of the high frequency of bilateral and recurrent disease. However, unilateral adrenalectomy alone (for unilateral lesions) or combined with partial contralateral adrenalectomy (for bilateral lesions) can be performed without inducing adrenal insufficiency and, in many cases, without recurrence at follow-up as long as seven years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Malignant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of the tumor is the primary therapy for malignant pheochromocytoma and can be curative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/81\">",
"     81",
"    </a>",
"    ]. Patients with metastatic disease should be treated by surgical debulking and chronic medical therapy with alpha-adrenergic and beta-adrenergic blockade to control symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/81\">",
"     81",
"    </a>",
"    ]. Malignant pheochromocytoma or paraganglioma can be quite indolent and observation to determine the pace of the disease is frequently the first management step. Systemic chemotherapy may be useful in some patients with excessive tumor burden and rapidly progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/22,81,82\">",
"     22,81,82",
"    </a>",
"    ]. A more experimental and noncurative approach for distant metastases has been the administration of high-dose 131-I MIBG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Radiofrequency ablation of hepatic metastases and cryoablation of bone metastases may be effective in selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of pheochromocytoma in adults\", section on 'Malignant pheochromocytoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent disease is a common problem in children with pheochromocytomas, particularly in those with familial disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. In one report of 14 children, four (28 percent) recurred within six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/12\">",
"     12",
"    </a>",
"    ]. The symptoms were those of pheochromocytoma but not necessarily the same as at initial presentation. Surgical removal of the recurrent tumor led to at least temporary cure of the disease because some children had multiple recurrences.",
"   </p>",
"   <p>",
"    Experience with recurrence in adults is much greater. In one series of 114 adults, pheochromocytoma recurred in 16 (14 percent), and the recurrence was malignant in 9 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/87\">",
"     87",
"    </a>",
"    ]. Not surprisingly, recurrence was more likely in patients with familial pheochromocytoma. This issue of late malignancy has been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, long-term monitoring is indicated in all patients, even those apparently cured. Most patients can be examined biennially, but those at increased risk for recurrent disease (eg, those with familial, large, extraadrenal, or bilateral disease) should be examined annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/87\">",
"     87",
"    </a>",
"    ]. Specific long-term follow-up guidelines after treatment of childhood cancer have been published by the Children's Oncology Group (available at",
"    <a class=\"external\" href=\"file://www.survivorshipguidelines.org/\">",
"     www.survivorshipguidelines.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/14/38121/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/27/1458?source=see_link\">",
"       \"Patient information: Pheochromocytoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pheochromocytomas and paragangliomas are rare tumors in children, accounting for approximately 1 percent of cases of hypertension. Those originating from the adrenal medulla are defined as pheochromocytomas, and the remainder are known as paragangliomas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presenting symptoms of these tumors in children are hypertension (64 percent), palpitation (53 percent), headache (47 percent), and effects related to the abdominal mass (30 percent); the \"classic triad\" of episodic headache, sweating, and tachycardia is an unusual presentation, particularly in children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As compared to adults, tumors in children are more likely to be familial, multicentric, or malignant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 percent of these tumors in children are a familial type, associated with multiple endocrine neoplasia (MEN) type 2A, type 2B, von Hippel-Lindau disease, neurofibromatosis type 1, or familial paraganglioma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pheochromocytoma in genetic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among apparently sporadic (non-familial) tumors, up to 25 percent will have unsuspected germline mutations of the genes involved in the above familial syndromes. Thus, genetic testing is appropriate for any child presenting with pheochromocytoma or paraganglioma. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Genetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=see_link\">",
"       \"Pheochromocytoma in genetic disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The optimal initial diagnostic to detect these tumors is a 24-hour urine collection for urinary fractionated metanephrines and catecholamines. The diagnosis is then confirmed with computed tomography or magnetic resonance imaging of the abdomen and pelvis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Urinary fractionated metanephrines and catecholamines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Radiologic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with known mutations for familial pheochromocytoma or paraganglioma, annual screening for the development of pheochromocytoma should begin in early childhood. The optimal screening test for this scenario is plasma fractionated metanephrines. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical resection is the primary treatment. We recommend all patients be treated with a medical regimen prior to surgery to reduce the risk of perioperative complications from catecholamine release (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest using alpha-adrenergic blockade with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/58/19364?source=see_link\">",
"       phenoxybenzamine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Beta-adrenergic blockade can be added AFTER the alpha-adrenergic agent is begun, if needed to treat tachycardia. Alternate choices for preoperative preparation include calcium channel blockers and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/25/2452?source=see_link\">",
"       metyrosine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Medical preparation for surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Up to 47 percent of these tumors in children are malignant; metastatic disease may become apparent many years after the initial presentation and surgical resection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Malignant disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/1\">",
"      Januszewicz P, Wieteska-Klimczak A, Wyszy��ska T. Pheochromocytoma in children: difficulties in diagnosis and localization. Clin Exp Hypertens A 1990; 12:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/2\">",
"      Wyszy��ska T, Cichocka E, Wieteska-Klimczak A, et al. A single pediatric center experience with 1025 children with hypertension. Acta Paediatr 1992; 81:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/3\">",
"      Fonkalsrud EW. Pheochromocytoma in childhood. Prog Pediatr Surg 1991; 26:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/4\">",
"      Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA. Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 2004; 28:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/5\">",
"      Ciftci AO, Tanyel FC, Senocak ME, B&uuml;y&uuml;kpamuk&ccedil;u N. Pheochromocytoma in children. J Pediatr Surg 2001; 36:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/6\">",
"      Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 2006; 118:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/7\">",
"      Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int 1991; 40:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/8\">",
"      Baguet JP, Hammer L, Mazzuco TL, et al. Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients. Eur J Endocrinol 2004; 150:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/9\">",
"      Caty MG, Coran AG, Geagen M, Thompson NW. Current diagnosis and treatment of pheochromocytoma in children. Experience with 22 consecutive tumors in 14 patients. Arch Surg 1990; 125:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/10\">",
"      Kaufman BH, Telander RL, van Heerden JA, et al. Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 1983; 18:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/11\">",
"      Kohane DS, Ingelfinger JR, Nimkin K, Wu CL. Case records of the Massachusetts General Hospital. Case 16-2005. A nine-year-old girl with headaches and hypertension. N Engl J Med 2005; 352:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/12\">",
"      Ein SH, Pullerits J, Creighton R, Balfe JW. Pediatric pheochromocytoma. A 36-year review. Pediatr Surg Int 1997; 12:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/13\">",
"      Pomares FJ, Ca&ntilde;as R, Rodriguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 1998; 48:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/14\">",
"      Walther MM, Reiter R, Keiser HR, et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 1999; 162:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/15\">",
"      Freier DT, Tank ES, Harrison TS. Pediatric and adult pheochromocytomas. A biochemical and clinical comparison. Arch Surg 1973; 107:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/16\">",
"      Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol 1992; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/17\">",
"      Albanese CT, Wiener ES. Routine total bilateral adrenalectomy is not warranted in childhood familial pheochromocytoma. J Pediatr Surg 1993; 28:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/18\">",
"      Ein SH, Shandling B, Wesson D, Filler Rm. Recurrent pheochromocytomas in children. J Pediatr Surg 1990; 25:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/19\">",
"      Webb TA, Sheps SG, Carney JA. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrime neoplasia, type 2. Am J Surg Pathol 1980; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/20\">",
"      Young WF Jr, Abboud AL. Editorial: paraganglioma--all in the family. J Clin Endocrinol Metab 2006; 91:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/21\">",
"      Bender BU, Alteh&ouml;fer C, Januszewicz A, et al. Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. J Clin Endocrinol Metab 1997; 82:3356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/22\">",
"      Perel Y, Schlumberger M, Marguerite G, et al. Pheochromocytoma and paraganglioma in children: a report of 24 cases of the French Society of Pediatric Oncology. Pediatr Hematol Oncol 1997; 14:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/23\">",
"      Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999; 229:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/24\">",
"      Pattarino F, Bouloux PM. The diagnosis of malignancy in phaeochromocytoma. Clin Endocrinol (Oxf) 1996; 44:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/25\">",
"      Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore) 1991; 70:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/26\">",
"      Lake CR, Zaloga G, Bray J, et al. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med 1989; 86:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/27\">",
"      Keiser HR. Surreptitious self-administration of epinephrine resulting in 'pheochromocytoma'. JAMA 1991; 266:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/28\">",
"      Lefebvre H, Richard R, Noblet C, et al. Life-threatening pseudophaeochromocytoma after toloxatone, terbutaline, and phenylephrine. Lancet 1993; 341:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/29\">",
"      Torres AD, Rai AN, Hardiek ML. Mercury intoxication and arterial hypertension: report of two patients and review of the literature. Pediatrics 2000; 105:E34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/30\">",
"      Louie AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardiol 1992; 70:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/31\">",
"      Moreau D, Weissman MM. Panic disorder in children and adolescents: a review. Am J Psychiatry 1992; 149:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/32\">",
"      Biederman J, Faraone SV, Marrs A, et al. Panic disorder and agoraphobia in consecutively referred children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/33\">",
"      Fogarty J, Engel C, Russo J, et al. Hypertension and pheochromocytoma testing: The association with anxiety disorders. Arch Fam Med 1994; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/34\">",
"      Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/35\">",
"      Dluhy RG. Pheochromocytoma--death of an axiom. N Engl J Med 2002; 346:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/36\">",
"      Walther MM, Herring J, Enquist E, et al. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/37\">",
"      Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/38\">",
"      Gardet V, Gatta B, Simonnet G, et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 2001; 19:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/39\">",
"      Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/40\">",
"      Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994; 15:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/41\">",
"      Langrehr JM, Bahra M, Kristiansen G, et al. Neuroendocrine tumor of the pancreas and bilateral adrenal pheochromocytomas. A rare manifestation of von Hippel-Lindau disease in childhood. J Pediatr Surg 2007; 42:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/42\">",
"      Mannelli M, Ercolino T, Giach&egrave; V, et al. Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet 2007; 44:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/43\">",
"      Hemmelgarn BR, McAlister FA, Grover S, et al. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006; 22:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/44\">",
"      Sawka AM, Jaeschke R, Singh RJ, Young WF Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/45\">",
"      Brain KL, Kay J, Shine B. Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population. Clin Chem 2006; 52:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/46\">",
"      Gerlo EA, Schoors DF, Dupont AG. Age- and sex-related differences for the urinary excretion of norepinephrine, epinephrine, and dopamine in adults. Clin Chem 1991; 37:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/47\">",
"      Perry CG, Sawka AM, Singh R, et al. The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. Clin Endocrinol (Oxf) 2007; 66:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/48\">",
"      Peaston RT, Lennard TW, Lai LC. Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. J Clin Endocrinol Metab 1996; 81:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/49\">",
"      H&eacute;ron E, Chatellier G, Billaud E, et al. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma. Ann Intern Med 1996; 125:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/50\">",
"      Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 1999; 340:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/51\">",
"      Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/52\">",
"      Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 1998; 83:2175.",
"     </a>",
"    </li>",
"    <li>",
"     Sawka AM, Singh RJ, Young WF Jr. Fractionated plasma metanephrines are highly sensitive but less specific than urinary total metanephrines and catecholamines in detection of pheochromocytoma. Program and Abstracts of The Endocrine Society's 83rd Annual Meeting, Denver June 20-23, 2001. Abstract #P1-642, p 285.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/54\">",
"      Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/55\">",
"      Elliott WJ, Murphy MB. Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels. Am J Med 1988; 84:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/56\">",
"      Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma. Hypertension 1991; 17:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/57\">",
"      Algeciras-Schimnich A, Preissner CM, Young WF Jr, et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008; 93:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/58\">",
"      Bouloux PG, Fakeeh M. Investigation of phaeochromocytoma. Clin Endocrinol (Oxf) 1995; 43:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/59\">",
"      Turner MC, DeQuattro V, Falk R, et al. Childhood familial pheochromocytoma. Conflicting results of localization techniques. Hypertension 1986; 8:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/60\">",
"      Miskulin J, Shulkin BL, Doherty GM, et al. Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 2003; 134:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/61\">",
"      Ta&iuml;eb D, Sebag F, Hubbard JG, et al. Does iodine-131 meta-iodobenzylguanidine (MIBG) scintigraphy have an impact on the management of sporadic and familial phaeochromocytoma? Clin Endocrinol (Oxf) 2004; 61:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/62\">",
"      Rozovsky K, Koplewitz BZ, Krausz Y, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. AJR Am J Roentgenol 2008; 190:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/63\">",
"      Lin JC, Palafox BA, Jackson HA, et al. Cardiac pheochromocytoma: resection after diagnosis by 111-indium octreotide scan. Ann Thorac Surg 1999; 67:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/64\">",
"      Shulkin BL, Thompson NW, Shapiro B, et al. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/65\">",
"      Pacak K, Eisenhofer G, Carrasquillo JA, et al. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/66\">",
"      Chew SL, Dacie JE, Reznek RH, et al. Bilateral phaeochromocytomas in von Hippel-Lindau disease: diagnosis by adrenal vein sampling and catecholamine assay. Q J Med 1994; 87:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/67\">",
"      Freel EM, Stanson AW, Thompson GB, et al. Adrenal venous sampling for catecholamines: a normal value study. J Clin Endocrinol Metab 2010; 95:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/68\">",
"      Turner MC, Lieberman E, DeQuattro V. The perioperative management of pheochromocytoma in children. Clin Pediatr (Phila) 1992; 31:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/69\">",
"      Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 1999; 161:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/70\">",
"      Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005; 60:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/71\">",
"      Col V, de Canni&egrave;re L, Collard E, et al. Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol (Oxf) 1999; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/72\">",
"      Pretorius M, Rasmussen GE, Holcomb GW. Hemodynamic and catecholamine responses to a laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Anesth Analg 1998; 87:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/73\">",
"      Clements RH, Goldstein RE, Holcomb GW 3rd. Laparoscopic left adrenalectomy for pheochromocytoma in a child. J Pediatr Surg 1999; 34:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/74\">",
"      Miller KA, Albanese C, Harrison M, et al. Experience with laparoscopic adrenalectomy in pediatric patients. J Pediatr Surg 2002; 37:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/75\">",
"      Walther MM, Keiser HR, Choyke PL, et al. Management of hereditary pheochromocytoma in von Hippel-Lindau kindreds with partial adrenalectomy. J Urol 1999; 161:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/76\">",
"      Lee JE, Curley SA, Gagel RF, et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/77\">",
"      Neumann HP, Bender BU, Reincke M, et al. Adrenal-sparing surgery for phaeochromocytoma. Br J Surg 1999; 86:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/78\">",
"      Neumann HP, Reincke M, Bender BU, et al. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma. J Clin Endocrinol Metab 1999; 84:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/79\">",
"      Diner EK, Franks ME, Behari A, et al. Partial adrenalectomy: the National Cancer Institute experience. Urology 2005; 66:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/80\">",
"      Evans DB, Lee JE, Merrell RC, Hickey RC. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 1994; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/81\">",
"      Ein SH, Weitzman S, Thorner P, et al. Pediatric malignant pheochromocytoma. J Pediatr Surg 1994; 29:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/82\">",
"      Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/83\">",
"      Shapiro B, Sisson JC, Wieland DM, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991; 35:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/84\">",
"      Goncalves E, Ninane J, Wese FX, et al. Familial phaeochromocytoma: successful treatment with 131I-MIBG. Med Pediatr Oncol 1990; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/85\">",
"      Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001; 93:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/86\">",
"      McBride JF, Atwell TD, Charboneau WJ, et al. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011; 22:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/14/38121/abstract/87\">",
"      Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997; 29:1133.",
"     </a>",
"    </li>",
"    <li>",
"     www.survivorshipguidelines.org (Accessed on January 19, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5850 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38121=[""].join("\n");
var outline_f37_14_38121=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIFFERENTIAL DIAGNOSIS OF SYMPATHETIC OVERACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHEOCHROMOCYTOMA IN GENETIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Familial paraganglioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Non-familial syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sporadic tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patients with symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Patients with family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients with known mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Biochemical testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Urinary fractionated metanephrines and catecholamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Plasma fractionated metanephrines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Radiologic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Medical preparation for surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Malignant disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5850|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/31/38385\" title=\"diagnostic image 1\">",
"      Pheochromocytoma MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/38/3691\" title=\"table 1\">",
"      Causes false positive pheo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/27/1458?source=related_link\">",
"      Patient information: Pheochromocytoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/54/21351?source=related_link\">",
"      Pheochromocytoma in genetic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/54/32616?source=related_link\">",
"      Treatment of pheochromocytoma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_14_38122="PMLE forearms";
var content_f37_14_38122=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64270%7EDERM%2F52975%7EDERM%2F76995%7EDERM%2F51455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64270%7EDERM%2F52975%7EDERM%2F76995%7EDERM%2F51455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows a 35-year-old woman with a symmetrical papulovesicular eruption on the forearms. Lesions were also present on the neck and lower legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Eric Ehrsam, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules developed on the dorsal hands, forearms, face, neck, and upper chest of this 40-year-old man with a history of sun exposure. The patient's history and symptoms were consistent with polymorphous light eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules developed on the dorsal hands, forearms, face, neck, and upper chest of this 40-year-old man with a history of sun exposure. The patient's history and symptoms were consistent with polymorphous light eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 12-year-old girl developed a pruritic eruption that consisted of discrete and coalescing erythematous papules on the face. The lesions were photodistributed and appeared within hours after intense sun exposure in the spring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38122=[""].join("\n");
var outline_f37_14_38122=null;
var title_f37_14_38123="Clin finding 22q11 deletion";
var content_f37_14_38123=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonimmunologic clinical findings in patients with chromosome 22q11.2 deletion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nonimmunologic clinical findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palatal anomalies&nbsp;",
"       </td>",
"       <td>",
"        69 to 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Speech delay",
"       </td>",
"       <td>",
"        79 to 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Learning disabilities",
"       </td>",
"       <td>",
"        45 to 90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac abnormalities",
"       </td>",
"       <td>",
"        49 to 83",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Developmental delay",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ophthalmologic abnormalities",
"       </td>",
"       <td>",
"        7 to 70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypocalcemia",
"       </td>",
"       <td>",
"        17 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric disorders",
"       </td>",
"       <td>",
"        9 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skeletal abnormalities",
"       </td>",
"       <td>",
"        17 to 45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal abnormalities",
"       </td>",
"       <td>",
"        31 to 37",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short stature",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dental",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: J Med Genet 1997; 34:798; Am J Med Genet 1992; 42:141; J Med Genet 1997; 34:453; Am J Med Genet 1999; 85:127; J Pediatr 1999; 134:193; Am J Med Genet 1998; 81:41; Genet Couns 1999; 10:3; Dev Med Child Neurol 2000; 42:422; Genet Couns 1999; 10:11; J Pediatr 1993; 123:406; J Pediatr 2011; 159:332.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38123=[""].join("\n");
var outline_f37_14_38123=null;
var title_f37_14_38124="Enuresis alarms PI";
var content_f37_14_38124=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Enuresis alarms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Device",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Dri-Sleeper",
"        </p>",
"        <p>",
"         Canada",
"        </p>",
"        <p>",
"         <a href=\"file://www.DRI-Sleeper.com\" target=\"_blank\">",
"          www.DRI-Sleeper.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Detector is clipped to standard disposable panty liner; beeper unit worn on shoulder",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Enurad",
"        </p>",
"        <p>",
"         UK Electronic",
"        </p>",
"        <p>",
"         Sweden",
"        </p>",
"        <p>",
"         <a href=\"file://www.enurad.com\" target=\"_blank\">",
"          www.enurad.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Wireless moisture alarm with radio transmission to an alarm clock. (Approved for use in Europe, but not in the US).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Malem Medical*",
"        </p>",
"        <p>",
"         Nottingham, England",
"        </p>",
"        <p>",
"         <a href=\"file://www.malem.co.uk\" target=\"_blank\">",
"          www.malem.co.uk",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Sensor pad in underwear; alarm unit on child's shoulder. Available with both auditory and vibratory alarms, or as a wireless unit.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Nite Train'r",
"        </p>",
"        <p>",
"         Koregon Enterprises",
"        </p>",
"        <p>",
"         Beaverton, OR",
"        </p>",
"        <p>",
"         <a href=\"file://www.nitetrain-r.com\" target=\"_blank\">",
"          www.nitetrain-r.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Moisture sensor in underwear or bed pad",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Nytone Enuretic Alarm*",
"        </p>",
"        <p>",
"         Nytone Medical Products",
"        </p>",
"        <p>",
"         Bluffdale, UT",
"        </p>",
"        <p>",
"         <a href=\"file://www.nytone.com\" target=\"_blank\">",
"          www.nytone.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Sensor clips on underwear; moisture alarm on wrist",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Potty Pager",
"        </p>",
"        <p>",
"         Ideas for Living",
"        </p>",
"        <p>",
"         Boulder, CO",
"        </p>",
"        <p>",
"         <a href=\"file://www.pottypager.com\" target=\"_blank\">",
"          www.pottypager.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Vibratory alarm",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Sleep Dry",
"        </p>",
"        <p>",
"         Star Child Labs",
"        </p>",
"        <p>",
"         <a href=\"file://www.sleepdryalarm.com\" target=\"_blank\">",
"          www.sleepdryalarm.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Beeper unit can be clipped to child's bedclothes near the ear",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         Wet-stop*",
"        </p>",
"        <p>",
"         Palco Labs",
"        </p>",
"        <p>",
"         Santa Cruz, CA",
"        </p>",
"        <p>",
"         <a href=\"file://www.wetstop.com\" target=\"_blank\">",
"          www.wetstop.com",
"         </a>",
"        </p>",
"       </td>",
"       <td>",
"        Sensor patch sewn into underwear (position can be adjusted for boys and girls); beeper unit attached by velcro to child's bedclothes near the ear. Available with both auditory and vibratory alarms.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Also available from The Bedwetting Store (",
"     <a href=\"file://www.bedwettingstore.com\" target=\"_blank\">",
"      www.bedwettingstore.com",
"     </a>",
"     ).",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38124=[""].join("\n");
var outline_f37_14_38124=null;
var title_f37_14_38125="Cutaneous vasculitis types";
var content_f37_14_38125=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of cutaneous vasculitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"12\" width=\"8%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        PAN",
"       </td>",
"       <td class=\"subtitle1\">",
"        c-PAN",
"       </td>",
"       <td class=\"subtitle1\">",
"        NV",
"       </td>",
"       <td class=\"subtitle1\">",
"        GP",
"        <br/>",
"        (WG)",
"       </td>",
"       <td class=\"subtitle1\">",
"        EGP",
"        <br/>",
"        (CSS)",
"       </td>",
"       <td class=\"subtitle1\">",
"        MPA",
"       </td>",
"       <td class=\"subtitle1\">",
"        CV",
"       </td>",
"       <td class=\"subtitle1\">",
"        RV",
"       </td>",
"       <td class=\"subtitle1\">",
"        IgA",
"        <br/>",
"        (HSP)",
"       </td>",
"       <td class=\"subtitle1\">",
"        UV",
"       </td>",
"       <td class=\"subtitle1\">",
"        LCV",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Vessel size",
"        </strong>",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Medium and small",
"       </td>",
"       <td>",
"        Medium and small",
"       </td>",
"       <td>",
"        Medium and small",
"       </td>",
"       <td>",
"        Medium and small",
"       </td>",
"       <td>",
"        Medium and small",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"       <td>",
"        Small",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Cutaneous findings",
"        </strong>",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa, infarcts",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa",
"       </td>",
"       <td>",
"        <p>",
"         Nodules, ulcers",
"        </p>",
"        <p>",
"         Lower extremity edema",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Nodules, ulcers, livedo racemosa, infarcts, palpable purpura",
"        </p>",
"        <p>",
"         Saddle nose deformity",
"        </p>",
"        <p>",
"         Strawberry gums",
"        </p>",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa, infarcts, palpable purpura",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa, infarcts, palpable purpura",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa, infarcts, palpable purpura",
"       </td>",
"       <td>",
"        Nodules, ulcers, livedo racemosa, infarcts, palpable purpura",
"       </td>",
"       <td>",
"        Urticarial papules, purpura, petechiae",
"       </td>",
"       <td>",
"        Urticarial papules, purpura, petechiae",
"       </td>",
"       <td>",
"        Urticarial papules, purpura, petechiae",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Systemic symptoms/involvement",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, neuropathy, hypertension",
"        </p>",
"        <p>",
"         Decreased renal perfusion",
"        </p>",
"       </td>",
"       <td>",
"        Weight loss, myalgia, fatigue, neuropathy",
"       </td>",
"       <td>",
"        Tuberculosis",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, neuropathy",
"        </p>",
"        <p>",
"         Glomerulo-nephritis",
"        </p>",
"        <p>",
"         Necrotizing granulomatous inflammation of respiratory tract",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, neuropathy",
"        </p>",
"        <p>",
"         Allergies",
"        </p>",
"        <p>",
"         Asthma",
"        </p>",
"        <p>",
"         Heart and GI involvement (esp if pANCA -)",
"        </p>",
"        <p>",
"         Glomerulo-nephritis and neuropathy (esp if pANCA +)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, neuropathy",
"        </p>",
"        <p>",
"         Alveolar hemorrhage",
"        </p>",
"        <p>",
"         Glomerulo-nephritis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, peripheral neuropathy",
"        </p>",
"        <p>",
"         Membrano-proliferative glomerulo-nephritis",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Weight loss, myalgia, fatigue, neuropathy",
"        </p>",
"        <p>",
"         Deforming arthritis",
"        </p>",
"       </td>",
"       <td>",
"        Arthritis, abdominal pain, renal involvement",
"       </td>",
"       <td>",
"        Fever, angioedema, athralgias, abdominal pain, Raynaud's phenomenon, uveitis, obstructive lung disease",
"       </td>",
"       <td>",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <strong>",
"         Helpful lab/study findings",
"        </strong>",
"       </td>",
"       <td>",
"        NEGATIVE ANCAs",
"       </td>",
"       <td>",
"        NEGATIVE ANCAs",
"       </td>",
"       <td>",
"        <p>",
"         PPD",
"        </p>",
"        <p>",
"         CXR",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         +c-ANCA",
"        </p>",
"        <p>",
"         +PR3",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         +p-ANCA",
"        </p>",
"        <p>",
"         +MPO",
"        </p>",
"        <p>",
"         Eosinophilia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         +p-ANCA",
"        </p>",
"        <p>",
"         No eosinophilia",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Hepatitis C+ plus cryoglobulins",
"        </p>",
"       </td>",
"       <td>",
"        High titer rheumatoid factor",
"       </td>",
"       <td>",
"        Urinalysis looking for renal involvement",
"       </td>",
"       <td>",
"        Low complement levels",
"       </td>",
"       <td>",
"        No systemic involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         DIF",
"        </strong>",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        +IgM",
"       </td>",
"       <td>",
"        +IgM",
"       </td>",
"       <td>",
"        IgA",
"       </td>",
"       <td>",
"        IgG, C3, fibrin, can also be seen along DEJ",
"       </td>",
"       <td>",
"        C3, IgM, IgA, IgG",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PAN: polyarteritis nodosa; NV: nodular vasculitis; GP (WG): granulomatosis with polyangiitis (Wegener's granulomatosis); EGP (CSS): eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); MPA: microscopic polyangiitis; CV: cryoglobulinemic vasculitis: RV: rheumatoid arthritis; IgA (HSP): IgA vasculitis (Henoch-Sch&ouml;nlein purpura); UV: urticarial vasculitis; LCV: cutaneous leukocytoclastic vasculitis/cutaneous leukocytoclastic angiitis; DEJ: dermal-epidermal junction; ANCA: antineutrophil cytoplasmic antibodies.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology; 56:3-23.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38125=[""].join("\n");
var outline_f37_14_38125=null;
var title_f37_14_38126="Late chronic papilledema";
var content_f37_14_38126=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late chronic papilledema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEeAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDgYo1ijVEGFHAFOpc8UAV9EzWIKOadjBpOhpevSoZaADNKo5pVWnlQKllhjP0pV6dKAcDFOHFSykOKntUMn3qlyaay5JJ60LYZGo5pkh+YgVMvHWkVPmYmqKsMQEjFOwV5qQLg+1IcnrWbYrkTSAZpBLxQ6DJpY0XPNDSBWHRqX5qUcHFSDCg8VGRuNZ3uK41l4pFAA5qVV7GlZMc9qafQuMuhA6ZqjNGVbI6VoYO6nSRArWilyi+FmfBIQcGriNnkdKqvHsanxPg4NOUb6oZfX7tJjH1pqHK4pwPT0rCw0RuMtTiMCngijIwc0XHcbxgZqRMEYqAnmpY8cUPYVywgHemyjFOPAHFMb5qlbk8wsfrUiqGNQDK1YibjPrRJBcUoMZzUDHae9WWYHpULpnrUx8xqRn3B3SVo2q4QCs1wfPH1rViIVR61tPZI6oysix0GDTkJ3Cowd3NSAgCsDqgydRu4NMI2nrTN57UrHjmhI6oDT80mTUlQoealJyM1bWp0IcTmmquRSDJNOZgF60rGiG4FMbFNaQA8VG7E1aix2B2C/WoS5xxTihPJowNtWkkRIjYFuuaQhVTJNOdscVDgu1NanPMhk+ZqZswSassgFRPWiZyVEUgMgGnqR3qLO0DFCue9btM+fiTGlQCo9+TTgwrNpl2JwAKRqZuOPWhmwOtTYsUmkD89ahUu7npt9KmWMY5oasPYkDg4olbniliRd3NTmNd3Sp0RWhBEpdhnOKnkQDpUiAK2BTJPvmk3cbYwfL9aa+KexGfeoZPapsSNYDtTVBBzTyBtpUAIwaGMazcUwEgg1K8fpSImaQiRDk8inluMGo87cU8jdjFSAzAzT1zTSNtPWq3Rb1VyOWHcOnNUZUKmtlF3Cq91BkZ704ztoyIysUoZsHBq3GCRWdIhRqv2kgYBac49UaEpQ596GXinueKEXINYk3ImQYzRGSKkYHGKYmAafQlsnJyvNRjKjJp24CkxupIi45CCDmnqM8U1FxTxwQalloQqc8U2R9o5qQvtBNUmczSnApxjfVlQVxIBumya0tvHAqpDEV5q3uwtObu9DZMfGtPfjmmKeOO9DNmoOumwBzUjcqKZGAeKl244qup3QGxDDUrMAcUUhTPWnbXU6kNZzjimfManCDZ0qLcAaafY1Q1UyeafhQaheU5+Wo2Lk5xVqLb1BomkIHGeKrSuSMKOKYWbdhqmRAR607cpDViJFLZzmpFAHIpx4zimg8UtzmmNcbhxUEiHBxwfpU/Q49aaepqkc0kZB6ClwDgYp23gUqjLV1SZ85EVkHamlCOlS45yaKzuWmRKWxil2sxqUDBpw6ZpNl3ERNoGKXPalXmlKc5qWybjkO1hU2QGzUSr8wqZo6llXFDc570zuSTTowc0OME5NILkLfrSAZpzLz1pCwA680MpCPgCohJjpTtu8nJpNu00hi+YeART0kFR8E9KdsB4FJpAK7DtQHxTDGTRsZTzSsirEpO4Uqn1zTF6YNKo56U0C0di3F7USnd2pkRI4PWlYnNQ1Zmb0ZWnjDLwOapKTG/pWmVOelVrqHjcBWkJdGOM+g8SbwPWrdvjvWXbkh8GtSJMoKipG2gpaBKozUSREtU7DmlQbWrO+hLZDIhBFSQxZXI61K+GHFEOBnmk5aE3GIuGpXwc07pTJOmQaOpSZUuXIXFLYREtuI4qGTMkmB0zWpax7IxWsnyxNk7IeyDFRsMcVYxmoZUOaxiwTGrkfSnlT17UsYyKmA+Wnc6qUhkSYqdh8vHWhRxzUqp8tF+p6VJ6FYj0FLUjbVzk1VllxwtUveOqGo6STHANVwCxqWOIvyalCDGKtNLY6FoIkSgAnrSsgoU4bFKTU3dySpNCG6dar5MfFXW6n0qFkBPIrRS7ksj3h6eqfLUMsRQkihJSOtO3YxnEey4NRscGlaWmM4PSmrnNJFBRxTozzUYJ2igEqc10yR8zFkzc01RiinH2qLFDhg0oxUeD2p/vUNDHqOcU40yNhnNSZUc9qTAcg5BPWphy2Kr+Zg8Ub2L8VNm0Ui3tCEc1UmcmQ7akXezfNSiPDNmhaDK+WIxQsZz81WAuD0p7LkdqlyKTIAuKJBuNPbAHIoRMrnNIZXZCDT8cUp4NDjgGgaBeOtTJzUK89anhBx7VMgZDLH6U1G2nmrUq8VWYZ7c01qQ2TxcnIqcoOtQW3oavJHnApSJk7ojWMYyajkjU8GrnlnGMUx4CelZq9zDmszFlh2PkVfsm3KAeane0LjJHSobeNkl2kVs3zxOlPniSTJgjFKI/lq4tuzDOMip0tcJkiudysY3M1ISQfSpEgOM1oCD2p/kkDgVDmDZmMmF6c1UlBCmtaWFh1FVLqMCP61cHqVFamZaxkyZrTiBNQWkeOavquKuo9bGknqIUwKicZqyVzTHXjmskxplMEqamjJzQyAipEUKOavc6aTuxyZJz2olm2LwarzTlchaijR5CM1fJ1Z6lLUcS0jcdKkjh9al8sIOKVBnnNLm7HbBiKNvA4FI/TNSAAg1GwpI2RCc5p2eOaVlweKjJ55q1qMCMUxs1Jz3pMetMlojPI5phhB5FSYpUbAxT1WxlMqSwgE4qERnOKuuu41GyYarUjlmzGVhxUmQagzxT0zXXJHyyHkYpUPPNNIJoAO4VBaJCcHinqpakjX161IODxWbYXECYPWl8snrSg4pwNJsLgkYyM81Ns29BTI/vjFTu2DUNl3EjHPtSvgE01G5psuSxxQMdkUp6c9KhCkd6flttS0MbJ83So9xAxmng9c5pmCWpjigX5m5qQp27UvllelPQ5XBqb9jW2hFs5q1ERs5piAZ5pyjLe1TLUhjzhqidBUjjb0NJtJxSRjIjRdrZ7Vo2zBgMVVER4q7ZREMMjilN21JT1LkMYkwMVowWIKnIptpDhwexrdtrdjjb6Vy1Z21RlUhZ6GJ9hw+MVlXtp5NyDjvXosGlvIAdtc/4p08wyKcd6jD4hSny3OjCq8rEOn2AlgU4qZtOwcYrpfDFmsunqSOcVrS6WpBwK86ri+WbRM48smjgm0/HRaVdOYKSQa7VNKXd0q02kDy8he1EcTd2MJz5TzK5tSucisXUYSuBXoOq6cUY4FchqUJa5CgV6OHqXkb0XczIYdqjipHXaPatF4AigEVVlTH0rXnuwbvqVCxHSoJJhnFS3BwCBVaCFpJMkcVqoq12OI+PJPFSuMAA96mKCNarsxZ6vZG8J66DRCD96p0UKMUgORSBj361m22enQlckdaQJjinj5hSMCTSTPRgyPHOO1NI55pxOMetO27kyKq50IgfG7BpjDmnutREHvWkSh3XFOUDFNA4FPTqKGJjWXjpUDDaT2q6wqtIuSaIsxkRtwAajYjINPkBFRuMitEc0kYyxcU8KBTc4UUqmuyR8oOIwKcEyM01jkU9DxWbGC9akUZpgPHSpEORmoZVhG607BxR1anheKTKBBtINOc5J9KCQBzQhG40ulxhECW5pzD5jUgUdRTGXDE0hrcSndhUbNnpQpwBUtFWFcelCAA89qdkD61HglqRpFFkYNHl88UqLge9WYxuxmobsUyFY8kinmLAzVkxhcYpJBxUcxi2UyO1SxRnipFh3c1btrZiRQ5Ixmx8NqG21dS22ngU6NCpAx0rX020aeUYGa5atTlV2ZrXYLG0ZgOOK3NPxFIFcfj61pR6WY7dSo5AqpdRFPmTqO1c0Kqq6G0ZKS5WdHYldoGOKyfGVgstmJgOlS6ReqyFW6itPUIhdaZKvXiuaMfZVUyad6VRMxvBLB7YJ3HFdLJF2/lXG+C38jUHgY/xV6A0YBAOK5cZTtVkbYtctT1IbS1GMkVYljCxnirSLtTiszVLkRRsT2rGEWeZZzkc5rkSgMciuCeMS6gSfug12Vy819IyqpxWdJojQlnwc4r2KNqcfeep3wSpqz3OfukXcQvOKyriFiTgV0U1kysd4pGtPl4FbxqJPQm6Ryq2RkbmpTbeUMAVum2C5wKz7/Cg10wbkS56mLdHtVQHDVNdNk1WLZPFamtMmDfMMVP5RxkCobcHcDV3cFXFZSdnZHp0JEKZHFBPSnLzmmupwaFuetTGyLk05D8uDTM8etLnABqrHUkNZctUbKamGTzjikkAx1qovUpFc8UbqVxkVHjIrSwNFgNnFI6jrUQbFDPx14qbamMhkgGcZqI/LnNSOeKgY/MBWiRzSMZjxTlGRTByKXJ28Gu1nySHnk4p3AxUa9uaeBk1DKHDrUqnAxUOMc0oznNQ1ctE2eRTy/HWoQ2DQTSsUSjnrTsYJqFH6ZqXeKXQCdCeM0OcsaSJgVpH4zUjQ2lIPWmDkin7uOaTHcAKVQc8ClB6VKo5qGzRMemasxnkVCODUi4rOQuYtjBAyakKArVRm4yDT45zjBrOxnImiwHrShYLgVTs490oJ6VddBu4qZWOee9i5FEZZFCjk13/AIa0kRwrI6iuZ8L2nnTqXHA716XZIojVFGAK8XG1m5ciFL3FYFgBXGP/AK1Zt9piOGyuCe4rpI4cUr24Zelc0KjiZRlZ3R5hc209lefKfkzXS6XdBrcowHIwRWtqOmpL1XmqcGmbDx1Fdc60aqV9z0PawnHXc5aFPs/iIMuApNegM2ERvUCuV1fTnhuFnUdDWvBeiS1VTwQMVtiYKpaa7BXftFFo10mytZN5D9pm254PUVNBcKAcmp4pEGWIFctFcurOFpwehXjsorVB8vzYzUM8QdelWp5xJnsKqlwtTKbk7I0jFvV7mHqFiv3sYxWRcxAKQorrpLZ7vgCqtxpexema6qLUdOoSajucZMhRDkYrntRBZzXbarAEQ5FcbqB2lhXpU3oZwfM7mBOuM5ql/HV24YkmqeOa3R2wLMPTNS7geDVVW2ingkkVPKehRRcVcLin7Bs5GaZHzip5j8mKzb1PXpPQr7QSaY4wKkQE80rjirTOuI2IYU8VDJ1qbcADUXXINVHctEYXPWmMuKmHGahlbOMVohMjfhTioicipGzioyOKtGEgzxUY4alz1pOT9KqxzyRidhSngUDlQcUGutnyCYqcCng0mOKUDioZSDNPQ5piqcGnx1LLQ4Dk03B5qSoyOeKRQY6YpxzupU6ilkwTQMfEcdKSWTkilhGTSsm5j2qdA6iQtxk1IwBFRL8p7Uu4moe4yROQKmVsEcVWGQamT3qZFoshwSBVnYCoIPWqYFSiQjismuxLJnAxgdas2sIbGaoq2WFaVjnzBSlojOTNO3t9seRT1jJcAc5q3HgR5x2qOyAa4H1rllKybMY3bOv8NR7EXPWu50/qCSKwNFgVbdPlGa6W3RQF4wa+eqS5pNk1JXdjRjORT9tRxk+gqdTmqjaxkkQvECc1XaMDnHWrrEVHNjbVJXZa0Mu6RJYyjjPaufmQxM23jnoK3rjIJJ9KyriMsSecV10qjiuVnRTdilG3A7CrSzlY+vFV3G08A/gKa+ZZFjTqTVSjzG6ipE6NJcSKELDBycd/Y1oQ2pT/AFlWNPtkgiUkfNVsjzHAA4qNI7GFSrraOw60CJxge1N1LasRJAqykKxjPPSsfWLhUQjNa04pPmOGXvM5LXHDbsciuJv0BJJro9cueWC4rkbp2OeTXdCVzrpU7GPe4VjiqO7J4q3fc571Ut/v811LY64xsWoo9wBp7w7cEU5SAMA1Yj5HPNRex3URsJwBmpn+YYFNWIMflp7BkHSo0voevRIACpxTWyaezA0u0mrR2IrSZFMHA5qWRT3FMH3cGtUVcYzE1E2cVLtpjciqTIbI8YpnWpQKQpgVVzKRAwpVTNKV5xT1HzAdapsxkc5k07PSmbhikBrskfGpk2/C80FzTc/LSjmsy0KCaejYPX60iqOc05doz0qWWiQcjNIgzmoTJ1A6UJJgClys0SLKjih1OeaiWYZp5mBzSsxtE0PWnFgC2aqrNhuKa7M7mhxCw9pAH4pwINRsi4600bu1JoasWlIBGTxU4dQM5qh81KobFQ4+ZZoiZSOtPSRSevNU4IWbvippbfy4y245FZ2W1yWkXYwucitXT1DEZ61hWchK89a1LG42yc1hUukyJR6HQSNtiAp2kgG6T61RlmDIMelXdDIM6k8c1xVNIMyirM9V0uMC1jNbtrzjisTSGDWKqO1bVp8vBNeEcs9zRQU8fSolYZ60NMoyM81fNZCiiTjrUM7cHFRNI7scZ204oSmTzVw3LehUePcajmtRs9qnLYYZ6Uk9wApFdlKN2LmfQxLuHYnGc0aNaETeY9WkInmwa1oYQoG3iu2UUo2NpVnCPKNdCBwKfbxZIPYVOIz9aUMF9K55QucvPoJNnyjXIa++A2a7CRx5ZJri/ET7iRVctxU3qcPqbbmYj9a5u+baTXQ34xI3p9a53UCGYg11Ukd9MyJ/mB5qBEweKlnGCeahVvnrr6HSi3DHuYVfEe2ImqcLbQCKtvIPLrGV7nZSuLAef8asuAyYqjAxDcVbEmccVElqetSK8sHHFRKWQ9KuFjuORUUhGMFT+VXGXRnYn3Krtk81FIQBVhkQt0YD6UySIYBBNaxaHdFfdTMinSJg8GoGyprVJMTJc0jcgVCZDSeYTyATTsYyJtufTIph45pDLjqKjMnNNJnPK5ze75RSq3XJpoPApvXivQkj49MsK4xSGTHSo9tBAHSs7ItMlDkjNABPPrTAeKcjcVLNUSKOeakCgioQc1IrYqWWmGzBxmnMnHWkHJzT8/NSvoO4kSgHmlY8mnHrxUZzuNF7gPHNKoIzTRxU8YyKzk7DsNGDxT2IAxTHG3kcUwknHrUblJFuFtpFPu5W8rAqBGAHNOBVsg9Km2twaGQzbEwTzV23nDEAGqEkS54ODVi0gJIwaU7NXCyep0UbkwjBq3p85jkXnv2rMgjkC8HNSwsyuOvWuGUbpoz5dT1/w9fKIEUsCxroopmBHPX2rzTwrdFZkLkYHavTo7tXhUrjOK8CslSnynPWjZ3RZjWYjcP1NXYIgoy5yTWVHeYPXvWhDP5g461jKeupldpFpsHpSNwlC5PWllXdGwHBxXRQV5GcmZF3OoOAeaqy5K8Zyaw7y7ki1cxyH5c11NmiXCqRg8V7LoKna5s4uEVIzIg0UobHFdNaFXiVhVO9tF8k47VU0u9COYWPStJpNcxlN+1jddDfYfKaz5XwSO1WfOBXr2rKvpdpzn8K5pu6sjKO5JLOuwqTXIa226Q8nFXbq7IY859qyL6bzAfX61pRi+paVnc5/U0HJzXKX3DGum1Pcc4NczdKzMc11QXKjspMxrljnmoYydwzV+5iBXtVeNRxW99Dsg0WkPyDoaVm7dqQJgZo9Rk5rJHfRSZNCQGBJqZpAORVWIZJGaViQKVrs9WlEs+au0+tQ+dn8Kh3YzmoS2DxVxgjqSLfm5NNaTI61XDUmCetUog0Eh5qu/XNTkYqPAwa0TsSyEgE9KRcU5u+KaAelVcxkxXCj1qFlGeKnkTioTVRZzyZzWRgCnAgCovSlHNehJHxqJQ2adnNRjtTz9KyaNUKPSlHtTfSnJ1qWaolUU48U0Zp3aoLHjrUmOTUSdRUxGTxSY7jlAzQQNxpyKc9KikO1jUhfUXZk1PEO2eKgViQMVKhIPpWci0OkXioCan++DjpUDLk0kUkAORT0H5VGvBpxfFDRQ/BLVahk8sVneYd2e1To24VE13JZu2d32q/E27Bxiubgchhityyk34U8k1x1IW1REkdLo8ixOMkV3emXZaNQT1rhdLtWbaSK7TTbcrGD6V42Kgps5pzRuRPu61pWj4rGSQKAAeavWuWYE9K4nSZg5XRvLKAuTT0lXBJPHvWe7hQORVG4uXJ2jI+lduHoO6kyEubQ57xftW+81OPetnwrqSm32lhmqGs2ons3YH5hXMaDdNDemJmxg45r1pzVSnePQ9FRjUocq6HqdxdhkOORXOXMphuA68ZNWklymCe1VLgCRSDzXLSrX0exw07U2a8F+jQgh+cVkalehmwDxWHcyz2shUZ21XnuWKbmFdMaN9ipU0tUTXtxluv5VSlclSahFyjkkkVWvLoBCFrdU2tDLVaFa7kyxBFYl4y7jzzU9zdkEg9TVKQ7wzGtorozaF1qZdzNgkGoIpOaLsfvDxSRr3FVKKSO6my2JCQO1O3ZPFQoKljUdaytY9OgTgBeaZKwOaR2OOcVC5O4URWp6tNjWOM1GDT2yajNbI6EyTGaeg65piZx2xUhPy8UhuRGxAODUbjA+tKTk0yXPSqSMpMbkdKVRgZqMggGk3mrsYyZI7cVCRlqCxpFPWmlY5qkjmMcClC0AEgU9VNehI+TSAClI70hyDThzWbLQqU/HNIoFSBfSoZqhOlPABpgHNKMgcUmO5MqcipujVWTPFTIxDc1m1oMtRFcc4qG6G5uOlTQxmQ5FOKHf8AMRgetRewdSvAoxzTX4NSSrg8VCxxijc0iTxZxxTH4JqW2YEYxUVwfmNZ9bGhEzYNRu4Pekds1ERVqIh5cVNC3aqwqeEc0SWgXNK3G4iui0O23TL0rB09S7qB1rutEt0iRXc815+IlZWRhVlZHS2VuiIuRzWolysce1TzWJJegINrAe1Lb3KhGZ+priVHRM89pyZqC8IkyTmtK31PjAPtXMCXzHJY4Wny3qRriPrVPDq5rZJWZ2K3inl2qC6vkJwn51y8F28iEsePSmrOc5LcUOOhCWp1CSB0cZyCK4i4P2fXCRwM1vWN9kn0ArmNSuPN1gbT3p4SDUZpnbhm1J+h31vchoVOecUwuTJnNZFtIyBM1fZjsD5+tZxh0OGbsy1OI5Y8NjdWDdFVJRqmuJ3UgqeKguE+0R7hy1ddH3XZijLTU5vUFeOQlGwKznuip/eCt66tztOBz6VzeoIVchhiu9SvubwknoyG6kDnIqJXIU1GQT0pofBKtT5bm3LbRDJE3k4xUYjKZFOIKtkdKmRgwwetRI3prsRQg5wc1My+nFKq457U12x0rLdnqUURSMVJ56UzfkGmysSfaog2M1qonpQehP8Aw00kEim5OKMetVY2THjpTWZsYAoHPQ0hOOKEh3IiWyM9acDuGTSuOKYDgVe5nKQPzxULjBqXcOTVeZyT1pxTuc8pC55phYg8UxjzknmlDCtEjkqSMENntUgNMAAFOU5rrkfNoTknmpIxSY59KcvH0qGWgA5qVR6U3IxT1BxWbNEB60AUHNAwBSGSLjPFKxAaog1OPJpW0GjX04gI3Q/Wo5mJJwBnNVrWQrx/OpDJhzWPK7sGtSF2bkUzHc1bMZfBHNMkgKjmlzIuLGwHnIpl0OelOj4ai4PHSp+0bFQim7cmrCrk80hABNWmFiILU8a8imZApyvj60mFjYsGERBrZh1N9yqOBXMwyEnk1pWILyAVyzgt2ZThfc6mO83qAM1qW+Gi3MeB61j2dvgKSeBU91eCNdinAqFDscskloie7vSSUjOKhhkbkEmqUThnz1q1HiokTaxrQS4iPNV3uCASKjDFV61Vkk521KiiEtTSjujHaO5bnFYVhc+bqJZjnmm6rfBLcxKeTVDTQwO/PNdSp8lJ36nVSTjFt9TvGvAdu09Ksi8zbEk5rkY7lwQGJrYjmX7IS3WuRQs0ck4FuK8EgZT3p8FwbdjvztNYUNx5c+7PGa6HyVuLYMnXFXopWZE48upHcTI3zLisfUbdJ0LAc066V4SQM49KiWViMCt07WNIRutDAdTDIQRkVBPGH5T9K176ISAkAZrLb92ea05rO6OqBEMhcOKTdtbB/OmXkwGCtQeYWANXKPMrnVSReVutQTPzTEl9c0hwSTURjY9OiMYsT7UwnnnFOllVVx3qlJIXPyitYxbO+JYe4AXAqMXNMjhJ5apGgG3jFVaK0NE0SJKCalJBPWqDIyHg0omIPNPk7DZaZh2qIvUfm5pV5pctjCbHEmom5Jz2qU8ZqLPU00c02ROSaRT27UOcnjNN/GtUjkmzJwdopVHNOHIFLjiumR4KHADueacvpUfen88Vmy0hxxmlVsHBpopStQy0Sk56UzrSIfWnZ4pFCxqM80rkeYRSoMmmyDDUhk8PJ56VKMbjmobc/MBUzj94eKiSDqW7ZlBJGaiuWeSQA9KVG2r15qSB1yS2M1g1Z3KS6kPlbccVHMMVbuZ0bAWq5XzBQr7s3jdorDJpDip3UKpHeqxzVrUq408mnAUAcU8CmBNF1rc0pMMGNYdvzItb9s3lRg45xWM1fQiWxsyXIVAo61SllHtVQTlySfyqN3O7k8UnGysYKBoxSgDipoZ9rZrHa42DANPhdnGT0rN09NQ9kbUt1nIU1TknIBY1S85lPPNMlmLRsMcU401cFSIVZp7kk9M1qRERcHtWTp7ATc1elcEn0rWqr6Fzjd2LkcoZwc8VamnZo9qnisleADmp7eYBsnmua1nch0yZZCB8xPFbel6mVXYTWCzAv2Ge1PV/LXipnFMiUE1ZnRXsgmXI4NYkkximIPSiC8Ow7jmqlzN5jcU432ZMafK7F+Rw4yKzb5MglabHcFTgmpWIIOT1rWHZmtrGLdA+XVRJsDBP51qXa9aoCAb+wHuK6YtJWZ10X3ITOQeTxTxMxXgE1YFsp7j8qQRqpIxmneJ6NOSIVhaQ5qVYVSpQSvTijBYVLk2dUZCL1z2pduaFUY96fgADNI0TImTdxVWaDPTrV9iAcioHIPNVGTTE5GawZDSpLjg1cdAxAIqvNBzxWqknuZSmO8xXApGIUVWZXQ0zzj3pqHY5Zsm79aYfrxTRJmkzk1aRyzkZ4bgU4ntSYHFLit5HjIF61IKZgZ4pQxHFQ0WiQdKXPFMB4608HioaGOKjbSbfQ0DLVIFAXPek9C0MUMDxSuDnkUoPNPPXmkUMjbDDg1Lv+Y0KAxpjr8x5pNXGkTiTORSAnGeargNjrmpY3xw1Q49jVJD26cU+N8cUyQjqKjU85zU2KTLEhLe4qJ14qSJgTzSzY7VC0YXK4U4qQLxQoJqQDaD2qmFx1pxMPStjO5cZrHgBD5rRjY7TSa1uKS0FLbCBRNIAPc1C7dTVYvuala5UIloDoSc1aSUBMCqcRB6mnB/yqGrluKZejcbcmmkgo/vUMeWqVB1HapSsyHGxnwuVuePWtWRlKdKypMLPxU7SErjNb1I3aG1ctpIMc5pyMAetU0Y4zS+Yc9aw5CWi6ZcP1qQyZ4PSqSn5sk1MDuxg1DiRYnL7RgVDK/YGmysR0NQM+cZoUQsPbgc9alS43Jtqs75GKiDbD1q4oEjRZd6e4qtIABinwTZ4NLcJzkVdrm8FYhVtvFNbB5prnbTFJb6U1E7YEg5FLnFM6H3oJz2p2OiLHjls09iGxUW7FKzg80rF3Gv9/wBqQ4zR1NOVOKvYTZF3zTH7+tSvxkZqs5qkjCchj4JOaqyxg5xU7GkwGxWsdDmnIosrCkDEHmrjqOlRSRdMVonc5pSKIOQKWmjkCng4rSR5iDpTX65pxOe9KAMVBSYinpUijJqIDtT1B7VLLRNnaKMsRimovrUwAAqWWiE/KwJqVssabJgmnqc0dCrCpweMU5uWxSdSKGOGpMaY7gU0jdR2oXmoZVxrKwHBqMNtNWHbAxUPU57UrjuL5uKd5pbpURxup24CkO5MjFTyKlzuxUW4FMHrTkzj2pDLCHDVcjcFDjpWdn0NTl9kYGeTQkVa6JJnABA61U6GnjOATTHOegoLhoLvIOBVmEZxk1WVMkVbjXatRJlMmBwOKkWTah9TUKe9VrmbBOPpShHmZG+g9hvnyOlTHiq1uflyepqVy3UHFXN3Y7Ey8DrQwH41GHOKljcYrMdhQvSpoziqjyHPFEcxBwaTRm0WJ2yc1Vd+TmnzSZNQZyenFCRCRJnK5zTGbPWnqOKAgPJpopCRvg1aE2Rg1U4zxRu+bFWjoh2J5FJ+lNX5FwKmhO4Y9qZJxmg6I6aCqvyg01l7ikD4FBbIOKRopCAZpj07ntQ3TB61SL5iJWIPOKsM2AM1VGd1TF9y/TiqtqJsZM2ACKgbGKkkPFQN0rRGEmMY80zfSsAaiJq0jlnIfvO6mk8800E/jR1q0jmlIojtTl5pBjHNKT6CtJHAhcHPtTweMVFuOeaeGAFQ0UhwHHNOB4qPcSRxTx05qGWhwNSryKhXrU0eeKlmsRQDu6U3kSHIxU3celNcAsaSZQ9OSKRh8xqMEqeOaRnIY8UWGkOycUFsLgVGZBjpTd/HFS0UOd+KaCce1NUEnJqVT2FJjQijP1owQaX7rUpOaRVgUkmpd5FNUALQSGoFYb5h3cYqyMlQWqFV5yBUhbAwaH5F9LEjHIqNTk0M/wAuBSLyPep6DuWYuxNTbweKqrntSk4P1qbA3cnnm2R8fnWbv8yQDqKfeTA/KKjtxxk1tFcsRxL0eB36VLvBqmhJqdTgVk0UkTgcUm7HAqNpsLgUoOfrSsx2JByKaWANMZj05zTScdaLESJCSTzSFh2pjncRg0+JN1JomxKmSOKUDg5pA2D04px5NShEYYA+lIeWz2ps3ytxSow2nNaJHRAngcqeakuCGGRVYMMcGlD9jTSN1qDYHHrSg5zSMoJBFMZiMinYpEnmYB9aMkioO3NTRE9KLDuIF5zSEdKmIII4pnOcU0JsZIcrjHaqpUnNWJSQc45xTFA8rPerWhhNldhUTA8irMhAGagznmtInLNjMUoU4zSD7wp5YYqjnkzNzwKVT1qvDL5sYYZFTKe1aPY44u48KOpp2MdKTtQelQy0KKVQaF6U9TkVDZokOUY5NSEjHFRk4puSamxoibdk9aXd82KhU96cSdxzRbQolxk5zTG6mhCc4FI3DGgQYBpQuTSAVIvFQykNKgcUmQKcxzULGkVcUsS1Lnio9+2lU7yKdgRIGJGKkQYI4oC/L9KUnFTe5otR7NtFQ7snNK7HFMHWmBIOfrTwPemRjmpVXLUmDY9GKjio5Z9oPrTpfkFZ8j72yaIxvqSg5kfA71fiXaNtVrRRuz3q5Gcvg05s0TFC4OaeOnNOChjTtmBnvWdy0xmwbhmrS7do4qq4+XJ7UqORxQ1cpkrgZ4qMgHrTyTtqNeSc9KDNiEAHg1JG34Ux1wCaRQcUmhIlZgDQXJ6UnXrUnl4Gc0thpEEp3UwHHarBXFN2ZParTNYkQ6E96cDxzSlO9AXkfWqLu0PV+MDrTSMmnlRkYpXHymmXzdSI8H+lPVjUWOTzTohhfYUWDmJVkOeelKzAc1CW600MSevSmomcphOxNRq3yYpXf5c+tVia0SOechZDn6VFnB604+tRHqTWqOVyJABnPtTHbk07PFV7iQIhY5wBninFGcmf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Don C Bienfang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38126=[""].join("\n");
var outline_f37_14_38126=null;
var title_f37_14_38127="Cystic hygroma CT V";
var content_f37_14_38127=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_14_38127=[""].join("\n");
var outline_f37_14_38127=null;
